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Abstract
Cirrhosis represents a major health issue for which no effective treatment
is available so far, except liver transplantation, hardly accessible for patients
because of a growing organ shortage. Stem cell therapy is emerging based on
their hepatocyte differentiation potential and immunomodulatory properties. The
purpose of this thesis is to evaluate the anti-fibrotic properties of Adult Derived
Human Liver Stem/progenitor Cells (ADHLSC) both in vitro and in vivo. We firstly
established that ADHLSC express and secrete several anti-fibrotic molecules
such as HGF, as compared to human hepatic stellate cells (HSC). As HSC
activation is a key element in fibrosis induction, we demonstrated that ADHLSC,
upon co-culture conditions, inhibit HSC proliferation and collagen secretion.
ADHLSC also induce HSC secretion of anti-fibrotic molecules including HGF
and MMP. Finally, we demonstrated that ADHLSC transplantation reduces liver
fibrosis in an animal model of chemically induced liver fibrosis.
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Liver fibrosis is a major health issue for which no effective treatment is 
available so far, except orthotopic liver transplantation (OLT). However, 
organ shortage is a daily reality. The efficacy of anti-fibrotic drugs has 
not been proven in humans. Hence, there is an urgent need to find 
alternative therapeutic strategies. Cell-based therapy may represent an 
attractive therapeutic option, based on the improvement of the hepatic 
inflammatory microenvironment, the inhibition of Hepatic Stellate Cell 
(HSC) activation or the induction of their apoptosis, the replacement of 
damaged hepatocytes and the promotion of residual hepatocytes 
regeneration. In particular, Mesenchymal Stem Cells (MSCs) represent 
an attractive therapeutic tool for the treatment of liver fibrosis, in terms 
of safety and efficacy. 
 
In this part, we will try to make an overview of the current knowledge 
in terms of cell therapy using MSC in a context of liver fibrosis. We will 
then discuss the relevance of using MSC to treat this condition and 
highlight the future perspectives in this field. 
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CHAPTER 1 
Liver fibrosis 
 
Progressive liver fibrosis is a major health issue for which no effective 
treatment is available so far, leading eventually to cirrhosis and 
orthotopic liver transplantation (OLT). However, organ shortage is a 
daily reality. Hence, there is an urgent need to find alternative 
therapeutic strategies. Mesenchymal Stem Cell-based therapy may 
represent an attractive therapeutic option, based on their 
immunomodulatory properties, their differentiation potential into 
hepatocytes allowing the replacement of damaged hepatocytes, their 
potential to promote the residual hepatocytes regeneration and their 
capacity to inhibit Hepatic Stellate Cell activation or to induce their 
apoptosis, in particular via paracrine mechanisms 
 
In this part, we will highlight the recent knowledge regarding the input 
of MSC-based therapy for the treatment of liver fibrosis and will discuss 
the perspectives in this field. 
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1.1. Liver fibrosis: a major health issue 
 
Liver fibrosis refers to the excessive accumulation of extracellular 
matrix into the liver parenchyma in response to chronic injury. Injuries 
may result from viral, autoimmune, cholestatic, toxic or metabolic 
disease, including nonalcoholic steatohepatitis. Chronic fibrosis 
progresses from fibrosis to cirrhosis characterized by septa formation 
and rings of scar surrounding nodules of surviving hepatocytes [1].  
Epidemiological data suggest that cirrhosis affects hundreds of millions 
people around the world [1]. It represents the 14th most common cause 
of death in adults worldwide (resulting in 1.03 million death per year) 
but the fourth one in central Europe [2]. In the European population, 
less than 1% (~0.1%) is affected by cirrhosis which corresponds to 14-
26 new cases per 100 000 inhabitants per year or an estimated 170 000 
deaths per year [3].   
 
1.2. Clinical aspects 
 
While mild fibrosis remains largely asymptomatic, its progression 
towards cirrhosis is a major cause of morbidity and mortality. Fibrosis 
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and distorted vasculature lead to portal hypertension and related 
complications, namely upper gastrointestinal bleeding from ruptured 
gastroesophageal varices, portal hypertensive gastropathy, ascites, 
renal dysfunction, hypersplenism leading to thrombocytopenia and 
hepatopulmonary syndrome[4]. Furthermore, cirrhosis is associated 
with hepatocellular insufficiency , impaired metabolic capacity and 
dysfunction of other organs such as the gastrointestinal tract [5], the 
kidneys [6], as well as the cardiovascular [7], respiratory [8] and skeletal 
systems [9]. Cirrhosis can lead to hepatocellular carcinoma [10]. 
 
1.3. Histology of liver fibrosis 
 
Following acute injury, liver parenchymal cells regenerate and replace 
the necrotic damaged cells. During this process, an inflammatory 
response is observed and accompanied by a limited deposition of 
extracellular matrix. In case of persistence of the injury, the 
regenerative capacity of parenchymal cells is impaired and dead 
hepatocytes are replaced by an abundant accumulation of the 
extracellular matrix, mainly secreted by activated hepatic stellate cells 
[11]. The initial distribution of this extracellular matrix will depend on 
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the etiology of liver injury. In chronic viral hepatitis and chronic 
cholestatic disorders, the fibrotic tissue will initially be located in the 
periportal areas. However, in alcohol-induced liver disease, the 
pericentral and perisinusoidal areas represent the initial localization of 
extracellular matrix deposition [12], probably because alcohol is mainly 
metabolized in these regions. 
Together with disease progression, the collagen fibers will 
progressively progress to bridging fibrosis, leading finally to cirrhosis. 
In advanced stages of fibrosis, the liver contains approximately 6 times 
more extracellular matrix deposition levels than a normal liver. 
including collagens (types I, III and IV), fibronectin, undulin, elastin, 
laminin, hyaluronan and proteoglycans [11]. The accumulation of 
extracellular matrix into the liver parenchyma results from both an 
increased synthesis and a decreased degradation by matrix 
metalloproteinases. 
Cirrhosis is defined histologically as a diffuse process characterized by 
fibrosis and the conversion of normal liver architecture into 
structurally abnormal nodules [13]. 
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1.4. Physiopathology of liver fibrosis 
 
1.4.1. Cellular effectors: extracellular matrix producing cells 
 
Extracellular matrix is mainly produced by Hepatic Stellate Cells (HSC), 
located in the space of Disse between hepatocytes and sinusoids. 
Following liver injury, HSC are “activated” and evolve to myofibroblast-
like cells following paracrine and autocrine signals. This activation is 
characterized by an increase in cell proliferation and extracellular 
matrix protein deposition, by a loss of the vitamin A droplets and by the 
acquisition of contractile features. Initiation represents the first 
activation phase and refers to early changes in gene expression and 
phenotype. HSC are stimulated by paracrine signals, including exposure 
to lipid peroxides and products released from damaged hepatocytes as 
well as biochemical signals from Kupffer and endothelial cells. In the 
perpetuation phase, the activated phenotype is maintained and fibrosis 
is generated. Autocrine as well as paracrine loops are implicated. 
Resolution refers either to the reversion to a quiescent phenotype or to 
a clearance through apoptosis [14]. At the structural level, activated HSC 
lose their big Vitamin A containing lipid droplets and up-regulate the 
expression of cell adhesion molecules like ICAM-1 and VCAM-1, 
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promoting the recruitment of inflammatory cells to the injured liver. 
The up-regulation of adhesion molecules expression has been studied 
in vitro and in vivo [15]. The expression of α-smooth muscle actin is also 
up-regulated and the secretion of pro-inflammatory cytokines is 
increased [16] [14]. 
During liver fibrosis development, HSC secrete matrix 
metalloproteinases (MMPs), calcium-dependant enzymes that 
specifically degrade collagens and noncollagenous substrates. The 
normal hepatic matrix is progressively disrupted and replaced by scar 
matrix, which will impair cell function. HSCs are the principal source of 
MMP2, MMP9 and MMP13 and stromelysin. Increased expression of 
MMP2 is characteristic of active fibrogenesis and is a key feature of HSC 
activation. Liver fibrosis is characterized by a failure to degrade the 
increased interstitial extracellular matrix, mainly composed of collagen 
type I. MMP1 is the main protease that can degrade collagen I. HSCs 
express MMP1 mRNA but little enzyme can be detected [14]. 
 
Beside HSC, other cellular sources contributing to extracellular matrix 
accumulation have been identified. These cells include portal 
fibroblasts (mainly implicated in biliary fibrosis) [17], circulating 
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fibrocytes, bone-marrow derived cells [18] as well as fibroblasts 
derived from epithelial-mesenchymal transition (EMT) of hepatocytes 
and bile duct epithelial cells [19]. EMT is characterized by a loss of cell 
adhesion, a repression of E-cadherin expression and an increased cell 
mobility.  This phenomenon represents an attractive target for liver 
fibrosis treatment. 
 
1.4.2. Other cellular sources involved in fibrogenesis 
 
• Biliary progenitor cells 
In biliary fibrosis, the proliferating biliary progenitor cells secrete 
several factors that attract and activate HSC into proliferative and 
extracellular matrix – producing cells. This phenomenon is amplified by 
several molecules secreted by the surrounding myofibroblasts and by 
inflammatory cells, like IL-6 and fibroblast growth factor [20].  
 
• Liver Sinusoidal Endothelial Cells  
In perisinusoidal fibrosis, the Liver Sinusoidal Endothelial Cells (LSEC) 
are activated and proliferate. LSEC contribute to extracellular matrix 
production; secrete cytokines and growth factors (such as TGFβ and 
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PDGF) that activate HSC as well as factors contributing to intrahepatic 
vasoconstriction. Myofibroblasts activate LSEC via secretion of 
angiogenic factors such as VEGF and angiopoietin-1 [21]. 
 
• Inflammatory cells 
CD4+T cells with a Th2 polarization also promote fibrogenesis. These 
cells secrete IL-4 and IL-13 which can stimulate the differentiation of 
fibrogenic myeloid cells and macrophages [22]. Th17 cells, induced by 
TGF-β1 and IL-6, secrete IL-17A, which activates directly 
myofibroblasts and indirectly by stimulating TGF-β1 release by 
inflammatory cells [23]. Regulatory T cells can either favor or inhibit 
fibrogenesis by secreting TGF-β1 (profibrotic) or IL-10 (anti-fibrotic) 
[20]. CD4+ Th1 cells have an anti-fibrotic effect [20]. 
NK cells can reduce fibrosis by killing activated HSC and by producing 
interferon γ  [24]. Monocytes play a key role in inflammation and 
fibrosis. They are precursor of fibrocytes, macrophages and dendritic 
cells [25]. Macrophages are fibrogenic during fibrosis progression and 
fibrolytic during its reversal [20]. 
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1.4.3. Key factors 
 
• Factors involved in HSC proliferation 
PDGF-β signaling is one of the best characterized pathways involved in 
HSC activation process. After PDGF-β binding to its receptor, several 
intracellular pathways are activated (including Ras-MAPK, PI3K-
AKT/PKB and PKC pathways) supporting cellular proliferation. In early 
HSC activation, a rapid induction of PDGF-β receptor is observed [26] 
[27]. 
Even if PDGF is the most potent mitogen towards HSC, other growth 
factors such as TGFα, EGF and VEGF are also able to stimulate HSC 
proliferation [28]. 
 
• Fibrogenic molecules 
TGFβ1 derives from both autocrine and paracrine sources. It represents 
the most potent fibrogenic cytokine in the liver. TGFβ1 recruits 
Smad2/3, leading to their phosphorylation and stimulation of 
fibrogenic gene expression [29]. Leptin also has a pro-fibrotic action 
through suppression of peroxisome proliferator-activated receptor-ɤ 
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(PPARɤ) [30]. Connective tissue growth factor (CTGF), secreted by HSC, 
is also fibrogenic.  
 
• Chemokines 
The migration of HSC to the site of injury is promoted by several 
chemokines (such as CCL5) secreted by HSC which express the 
appropriate receptors [28]. 
 
• Neurotransmitters 
Following chronic liver injury, the local neuroendocrine system is up-
regulated and HSC express different receptors, including those 
regulating cannabinoid signaling, and secrete endogenous cannabinoid. 
The activation of CB1 receptor is pro-fibrogenic while CB2 receptor is 
anti-fibrotic. Opioid and serotonin pathways as well as thyroid 
hormones have a pro-fibrotic effect [28]. 
 
• Inflammatory pathways 
Finally, inflammatory pathways are also involved in HSC activation 
process. HSC secrete inflammatory chemokines and interact directly 
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with immune cells through expression of adhesion molecules, including 
ICAM-1 and VCAM-1 [31]. Moreover, apoptotic hepatocyte DNA can 
interact with Toll like receptor 9 expressed on HSC, repressing HSC 
migration and increasing collagen production [32]. 
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CHAPTER 2 
Current therapeutic approaches 
 
2.1. Anti-fibrotic drugs  
 
Liver fibrosis is a dynamic process that may undergo reversal [33]. The 
best aim of anti-fibrotic therapy is to eliminate the underlying disease 
process. In case of impossibility to treat the underlying process, anti-
fibrotic therapy would be ideal. Currently, there is no anti-fibrotic drug 
available in clinical setting [34] [1] [35]. Specific agents are under 
investigation. However, none has been approved as anti-fibrotic 
therapy.  
The use of anti-fibrotic drugs has been reported in preclinical and 
clinical studies. This approach targets several aims[36] [37] [38], such 
as: (1) downregulate HSC activation [39] [40] [41] [42] [43] [44] [45] [46], 
(2) neutralize proliferative, fibrogenic, and contractile responses of HSC 
[47] [48] [49] [50] [51] [52] [53], (3) promote apoptosis of HSC [54] [55], 
(4) promote matrix degradation [56] [57], (5) reduce inflammation [58] 
[59] [60] [61] [62] [63] and (6) inhibit collagen I cross-linking [64], as 
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shown in Table 1. Overall, anti-fibrotic agents have been shown to be 
highly effective in animal models and represent potential anti-fibrotic 
drugs. Several anti-fibrotic agents that have been transitioned to clinical 
studies are peroxisomal proliferator-activated receptor gamma (PPAR-
γ) agonist [40] [41], interferon γ (IFN-γ) [43] [44], angiotensin II 
antagonist [50], colchicine [52], interleukin 10 (IL-10) [59], anti-tumor 
necrosis factor alpha (TNF-α) [61], ursodeoxycolic acid [63], and 
antioxidant [46].  
Given the supportive preclinical data, however, the data in human are 
mixed. Moreover, most of these studies are performed in small numbers 
of patients during a short period of time, whilst fibrosis is a long lasting, 
slowly progressive event. Human studies have examined the effect of 
PPAR-γ agonist [40] and IFN-γ [43] in patients with liver fibrosis. Beside 
promising results in small scale studies [40] [43], longer and larger 
studies failed to demonstrate any beneficial effect [41] [44]. 
Compared to preclinical studies, clinical studies of several anti-fibrotic 
agents have been shown to yield dramatically different results [46] [52] 
[59] that may be due to several reasons. In animal model, anti-fibrotic 
drugs were investigated against the development of fibrosis. On the 
39 
 
other hand, in real clinical setting, and in most of clinical trials, patients 
have advanced fibrosis. Potential of collagen degradation also differs 
between rodent model and human as a consequence of different cross-
linking of ECM. Compared to human fibrosis, that requires years to 
develop, fibrosis in rodent takes place in weeks or months and contains 
less chemical cross linking. In addition, differences in pharmacokinetics 
of anti-fibrotic drugs between animal model and human contribute to 
the different results [37]. 
Furthermore, a crucial issue that remains to be investigated is how to 
translate preclinical evidences of other potential anti-fibrotic agents 
into benefit for patients. In general, the development of anti-fibrotic 
drugs in human meets several obstacles [36]. First, liver fibrosis is 
slowly progressive event, requiring probably several years of follow up 
to establish efficacy. Second, gold standard tool to evaluate fibrosis 
remains histology. Patients and physicians may be reluctant to perform 
repeated biopsies, due to possible adverse events [65]. Moreover, 
sampling error in liver biopsy and inter-observer variability may 
interfere with the results [66]. For all these reasons, noninvasive 
diagnostic tools would be highly desirable, ranging from physical 
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examination finding, laboratory investigation, radiographic test, to 
specific serum marker [37]. Transient elastography has also been 
developed to measure liver stiffness using ultrasound principle [67].  
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Table 1: Preclinical and clinical studies representing the development of anti-fibrotic strategies
Preclinical/ clinical results Disease model Reference
Peroxisomal proliferator-
activated receptor gamma (PPAR-
γ) agonist (Pioglitazone)
Inhibition of HSC activation and amelioration 
of hepatocyte necroinflammation in rats 
after 8 weeks
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[39]
Reduction of steatosis, but not fibrosis 
compared to placebo, in patients with NASH 
after 6 months (26 pioglitazone; 21 placebo)
Nonalcoholic steatohepatitis (NASH) [40]
No benefit of pioglitazone over placebo in 
term of steatosis and fibrosis in patients 
with NASH after 96 weeks (80 pioglitazone; 
83 placebo) 
Nonalcoholic steatohepatitis (NASH) [41]
Interferon gamma (IFN-γ)
Inhibition of the activation of HSC and 
extracellular matrix production
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[42]
Improvement of fibrosis scores in patients 
with chronic HBV infection after 9 months 
(54 IFN-γ; 29 control)
Chronic HBV infection [43]
No reversion of fibrosis in patients with 
advanced liver disease after 1 year (IFN-γ1b 
100μg 169; IFN-γ1b 200μg 157; placebo 162)
Chronic HCV infection [44]
Antioxidant (Vitamin E)
Protective effects against liver damage and 
cirrhosis in rats
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[45]
No benefit on liver function tests in patients 
with mild to moderate alcoholic hepatitis 
after 1 year (25 vitamin E, 26 placebo)
Alcoholic hepatitis [46]
Anti-Transforming Growth Factor 
beta (TGF-β)
Supression of fibrosis in rats after 3 weeks Dimethylnitrosamine-induced liver fibrosis [47]
Short interference RNA (SiRNA)
Inhibition of the expression of TGF-β1 and 
attenuation of liver fibrosis in rats
High-fat diet and CCl4-induced model of liver 
fibrosis
[53]
Endothelin antagonist
Nonpeptide endothelin-A receptor 
antagonist, LU 135252, reduced collagen 
accumulation in rats after 6 weeks
Secondary biliary fibrosis [48]
Angiotensin system inhibitor
Olmesartan, an angiotensin II type 1 receptor 
blocker, decreased expression of collagen 
genes and attenuated liver fibrosis in rats 
after 15 weeks
Methionine-choline-deficient rat model of 
NASH 
[49]
Angiotensin-converting enzyme inhibitors 
(ACEi) and angiotensin receptor-1 blocker 
(ARB) did not retard the progression of liver 
fibrosis in patients with advanced liver 
fibrosis after 3.5 years (66 ACEi/ARB, 126 non-
ACEi/ARB, 343 no antihypertensive 
medication)
Chronic hepatitis C [50]
Colchicine
Colchicine and colchiceine (metabolite of 
colchicine) prevented increase in collagen 
synthesis and increased the intracellular 
degradation of collagen rats 
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[51]
Colchicine improved fibrosis marker, but not 
histological finding, in patients with hepatic 
fibrosis after 12 months (21 colchicine; 17 
control)
Liver fibrosis of various etiologies [52]
Gliotoxin
Morphologic alterations typical of apoptosis 
of HSC in vitro (activated rat and human HSC) 
and reduction of the number of activated 
HSC in rats
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[54]
Sulfasalazine
Induction of activated HSC apoptosis, by 
inhibiting nuclear factor kappa B-dependent 
gene transcription, both in vitro (activated 
rat and human HSC) and in vivo 
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[55]
Antifibrotic drug
Downregulation of HSC activation
Neutralization of proliferative, fibrogenic, and contractile responses of HSC
Promotion of HSC apoptosis
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2.2. Orthotopic liver transplantation 
 
Currently, orthotopic liver transplantation (OLT) remains the most 
effective treatment for this condition. Over time, the survival rate after 
OLT has progressively increased, reaching currently 83% after one year 
in adults. Liver cirrhosis remains the main indication for OLT in Europe 
(59%) (EASL 2013).  In children, a survival rate of 93.2% has been 
Matrix metalloproteinase (MMP) 
inducer
Urokinase-type plasminogen activator, an 
initiator of the matrix proteolysis cascade, 
induced collagenase expression and reversal 
of fibrosis rats
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[56]
Tissue inhibitor of matrix 
metalloproteinase (TIMP) 
inhibitor
Polaprezinc, a zinc-carnosine chelate 
compound, attenuated fibrosis by inhibiting 
TIMP expression during a later phase, thus 
promoting fibrinolysis, in mice after 10 
weeks
Dietary methionine and choline deficient 
(MCD)-induced NASH
[57]
Interleukin 10 (IL-10)
Inhibition of HSC activation and decrease of 
the expression of TGF-β1, MMP-2, and TIMP-
1 in rats
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[58]
Anti-inflammatory effect, but increased HCV 
viral burden via alterations in immunologic 
viral surveillance, in patients (30 subjects for 
3-dose trial)
Chronic hepatitis C [59]
Anti-TNF-α
Infliximab decreased necrosis, 
inflammation, and fibrosis in rats
Dietary methionine and choline deficient 
(MCD)-induced NASH
[60]
Infliximab improved Maddrey's score in 
patients after 28 days (20 subjects)
Alcoholic hepatitis [61]
Ursodeoxycholic acid (UDCA) Reversion of liver damage in rats 
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[62]
Reduction of periportal necroinflammation 
and, if initiated at the earlier stages I-II of 
the disease, delay of the progression of 
histologic stage in patients after 2 years (200 
UDCA, 167 placebo)
Primary biliary cirrhosis
[63]
Inhibition of collagen I cross-linking
Anti-Lysyl oxidase-like-2 (LOXL2)
Reduction of liver fibrosis, decrease in the 
number of myofibroblasts and lower p-
Smad3 signal
Carbon tetrachloride (CCl4)-induced liver 
fibrosis
[64]
Reduce inflammation
Promotion of matrix degradation
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reported 10 years after OLT [68]. However, over the last 10 years, the 
annual number of OLT has stopped growing because organ donation 
has not kept up with demand, leading to an increased mortality and 
morbidity in the waiting list [69]. Moreover, some limitations such as 
operative risk, post-transplant rejection, recurrence of the pre-existing 
liver disease and high costs have to be taken into account [70]. 
Moreover, fibrosis often develops in the liver grafts as early as one year 
after transplantation. Portal fibrosis is present in 31% of liver grafts 
one year after pediatric OLT [71] and in 74% in the long term  [72] [73]. 
 The prevalence increases to 65% five years after OLT and to 71% at 10 
years, with 29% of severe fibrosis [74]. 
 
2.3. Cell-based therapy 
 
Cell-based therapy has been proposed as a less invasive potential 
alternative to OLT. The rationale is mainly based on the ability of 
several cells to (1) improve the hepatic inflammatory 
microenvironment, (2) inhibit the activation or induce apoptosis of 
HSC, (3) replace damaged hepatocytes and (4) promote the 
regeneration of residual hepatocytes. 
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• Isolated hepatocytes 
Hepatocyte transplantation has provided the proof-of-concept that cell 
therapy could be used to treat some liver diseases such as metabolic 
disorders and acute liver failure [75] [76] [77]. A decrease of liver 
fibrosis and a restoration of phospholipid secretion were also observed 
in a mouse model of progressive familial intrahepatic cholestasis type 
III after hepatocyte transplantation [78]. The feasibility and safety of 
this technique is supported by the numerous clinical trials performed 
with hepatocytes. 
However, the efficacy seemed to have a limited durability, with a 
progressive decrease of the observed effects [79]. Moreover, 
hepatocytes are poorly resistant to cryopreservation, which can be 
limitative as fresh hepatocytes are not always available [80]. Moreover, 
hepatocytes are rare material and cannot be expanded in vitro.  
Therefore, finding a new and readily available cell source was 
primordial. 
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• Stem/progenitor cells 
Stem/progenitor cells have progressively emerged as an attractive 
alternative to hepatocytes in the context of cell-based therapy. 
Stem/progenitor cells are able to proliferate in culture, are resistant to 
cryopreservation and have three interesting characteristics: plasticity, 
migration and engraftment.  
 
o Embryonic stem cells and induced pluripotent stem cells 
Pluripotent embryonic stem cells (ESC) are derived from the inner cell 
mass of blastocyst embryo. Several in vivo studies revealed the potency 
of ESC to differentiate into hepatocyte-like cells and to reduce induced 
liver fibrosis. Mouse ESC-derived green ﬂuorescent protein (GFP)+ cells 
injected into CCl4-injured mice [81], undifferentiated mouse ESC 
injected into CCl4-treated mice [82] [83], and human differentiated ESC 
transplanted into CCl4-injured SCID mice [84] showed hepatic 
differentiation, integrated into liver parenchyma, and reduced liver 
fibrosis without evidence of tumorigenicity. The result of these studies 
should be further confirmed, however, since teratoma formations were 
observed in other studies. Splenic teratomas were formed in mice with 
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induced hepatocellular injury 35 days after administration of 
undifferentiated mouse ESC and 60 days after transplantation of mouse 
ESC-derived alpha-fetoprotein-producing cells [85]. Injection of 
undifferentiated mouse ESC into the spleen of immunosuppressed nude 
mice also gave rise to splenic teratomas [86]. Although ESC have the 
ability to differentiate into hepatocytes, their malignant potential and 
ethical issues still remain the major obstacles to develop ESC treatment 
in clinical settings. Moreover, there may be genetic/epigenetic changes 
and immune rejection problems when ESC are transplanted, due to 
their allogeneic nature [87]. 
To avoid these issues, new technologies have enabled tissue cells to 
become induced pluripotent stem cells (iPSC). Along with the 
development in the field of stem cell reprogramming, iPSC represent 
promising stem cells in cell-based liver therapy. Song and colleagues 
provided evidence of hepatocyte differentiation of human iPSC for the 
first time [88]. At various differentiation stages, human iPSC-derived 
hepatic cells from different organs repopulated the liver of mice with 
induced liver cirrhosis. The engraftment potential of differentiated iPSC 
was comparable to that of human hepatocytes and was higher than that 
of undifferentiated human ESC or iPCS [89]. iPSC provide an unlimited 
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source for regenerative medicine since patient-specific cells produce 
neither ethical issue nor problem of cell rejection. Despite iPSC’s 
promise, potential risk of genetic manipulation and mutagenesis should 
be considered before any clinical application. Other issues remains to 
be addressed in recruiting iPSC are (1) the source of iPSC, whether 
patient-specific iPSC should be derived from diseased tissue portion, 
(2) directed hepatic differentiation protocol, and (3) extensive 
characterization of hepatic differentiation [90].  
 
o Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) have extensively been investigated as 
potential therapeutic options for the treatment of various degenerative 
diseases and immune disorders, mainly because of their differentiation 
potential and immunoregulatory properties [91]. As compared to 
embryonic stem cells, MSCs do not give rise to ethical problems and 
have a safer profile in terms of oncogenicity [92]. 
The different MSC’s properties make them an attractive therapeutic tool 
in the context of liver fibrosis, as it will be discussed in the following 
paragraphs.  
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CHAPTER 3 
MSC’s properties and their potential use 
in regenerative medicine 
 
3.1. General features 
 
In 2006, the International Society for Cellular Therapy proposed 
minimal criteria to define human MSCs [93]. First, MSCs must be plastic-
adherent when maintained in standard culture conditions. Second, > 
95% of the MSC population must express CD105, CD73 and CD90, and 
lack the expression (< 2% positive) of CD45, CD34, CD14 or CD11b, 
CD79α or CD19 and HLA class II surface molecules. Third, MSCs must 
differentiate into osteoblasts, adipocytes and chondroblasts under 
standard in vitro differentiating conditions [93]. 
MSCs are spindle-shaped fibroblast-like cells and have the ability of 
self-renewal. They can be isolated and expanded with high efficiency 
[94].  
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3.2. Differentiation potential 
 
The high degree of plasticity of MSCs has widely been described during 
the last decade [95] [96] [97] [98]. 
MSCs have been shown to have the ability to differentiate into a variety 
of mesodermal cell lineages (including adipocytes, osteoblasts, 
chondroblasts, myocytes and cardiomyocytes) and into non-
mesodermal cells (such as hepatocytes and neurons), depending on 
their microenvironment [99]. 
In particular, in vitro models provided evidence of the differentiation 
potential of MSCs into hepatocyte-like cells with functional properties 
such as albumin and urea production, glycogen storage, LDL uptake and 
phenobarbital-induced cytochrome p450 expression [100] [101].  
Moreover, the in vivo hepatic differentiation of MSCs has been 
demonstrated in rats [102] [103], mice [104] and humans [105]. 
 
Adult-derived human liver stem/progenitor cells (ADHLSC) are 
obtained from healthy livers after a two-step collagenase perfusion and 
primary culture of the parenchymal fraction. The cells display a 
mesenchymal phenotype and a preferential hepatocyte expression 
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pattern [106] [107]. The cells cannot differentiate into other cell types 
(such as adipocytes and osteoblasts), like extra-hepatic MSCs. However, 
ADHLSC are able to differentiate into hepatocyte-like cells in vitro, after 
treatment with a cocktail of specific growth factors and cytokines. The 
differentiation was observed at the morphological, gene expression and 
functional levels. In vivo, once intrasplenically transplanted in 
immunodeficient mice, ADHLSC are able to migrate, engraft into the 
murine liver parenchyma and differentiate into hepatocyte-like cells up 
to 2 months post-transplantation. Recently, we demonstrated that 
engrafted ADHLSC are able to proliferate and participate to mouse liver 
regeneration after hepatectomy [108]. The cells have been successfully 
expanded in large scale and GMP conditions and transplanted in human 
trial [109]. The cells were approved as technological innovation by the 
European patents office in 2009 and as orphan drugs for the Crigler 
Najjar syndrome and urea cycle defects by the European Medicines 
agency. The technology has been successfully transferred to a spin-off 
company, Promethera Biosciences, for industrial and clinical 
developments. 
 
52 
 
This hepatic differentiation potential is essential for MSC-based 
therapies in the context of chronic liver diseases in which the injured 
hepatocytes are unable to regenerate [69]. 
 
3.3. Immunomodulatory properties 
 
The ability of MSCs to modulate the immune response is attracting 
great interest, in the context of cell-based therapy and allogeneic 
transplantation. 
It is well known that MSCs suppress the activity of cells from both 
adaptive and innate immunity. Indeed, MSCs can inhibit the 
proliferation of CD8+ cytotoxic lymphocytes and increase the relative 
proportion of CD4+ T helper-2 lymphocytes and CD4+ regulatory T 
lymphocytes [110] [111]. This effect on T lymphocytes indirectly 
suppresses the function of B lymphocytes as their activation is mainly T 
cell dependent. Moreover, MSCs can modulate B cells functions by 
inhibiting their proliferation, differentiation into antibody-secreting 
cells and chemotaxis. Soluble factors like transforming growth factor 
β1, hepatocyte growth factor, prostaglandin E2 and indoleamine 2,3- 
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dioxygenase seem to be implicated in this immunosuppressive activity 
[112]. 
MSCs also exert inhibitory effects on monocytes, dendritic cells, 
macrophages and NK cells, which belong to the innate immune system. 
MSCs inhibit the maturation of monocytes into dendritic cells, which 
play a role in antigen presentation to naïve T-cells. MSCs also inhibit the 
secretion of TNF-α, INF-ɤ and interleukin-12 by dendritic cells and 
increase their secretion of IL-10, reducing their proinflammatory 
potential [113] [114].  This inhibitory effect exerted by MSCs seems to 
be mediated by soluble factors, including prostaglandin E2 (PGE2) 
[115]. MSCs are also able to suppress NK cell’s proliferation, cytolytic 
activity and secretion of cytokines. The role of PGE2 and indoleamine 
2,3- dioxygenase has been established [116]. 
Thanks to all these characteristics, MSCs have generated a great interest 
for their potential use in regenerative medicine. 
 
Altogether, while having the least potential to differentiate into 
endodermal cells compared to ESC and iPSC, MSCs can be readily 
obtained and expanded into large quantities. Moreover, MSCs are 
resistant to cryopreservation and maintain a stable phenotype 
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following the passages in culture [117]. Furthermore, the use of MSC 
sidesteps many obstacles for conducting human trials, such as ethical 
concerns, risk of rejection, and teratoma formation. Considering the 
unrelieved concerns regarding safety and efficacy, there has not been a 
clinical trial using human ESC and iPSC-derived hepatocytes for liver 
regeneration. 
 
3.4. Homing and engraftment 
 
MSCs have the potential to migrate to the injured site and thereafter to 
engraft into the concerned organ. This involves their ability to migrate 
across the endothelial cells and to integrate the organ.  
It is well known that injured tissues express several receptors and 
ligands (such as CXCR4 and SDF-1) that facilitate the migration of MSCs 
to the damaged sites. Furthermore, chemokines are released following 
injury, creating a gradient followed by MSCs [118]. This represents a 
key mediator of trafficking of MSC to the site of injury. Finally, MSCs 
also express some integrins, selectins and chemokine receptors 
involved in the adhesion and migration of leucocytes [119] [120]. 
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The advantage of this property is that MSCs can participate to liver 
regeneration and ensure continued delivery of trophic signal molecules. 
However, follow-up studies are necessary to assess the long-term 
engraftment rate of MSCs. 
 
3.5. Therapeutic significance of MSC secretome 
 
Soluble factors secreted by MSC have been described to play an 
important role in liver regeneration and to protect hepatocytes from 
cell death. It has been demonstrated that bone marrow MSC 
conditioned medium has an anti-apoptotic and pro-mitotic effect on 
cultured hepatocytes. Moreover, a systemic infusion of MSC conditioned 
medium could inhibit hepatocytes cell death and enhance liver 
regeneration in vivo, in a D-galactosamine-induced rat model of acute 
liver injury [121]. Zhang and colleagues demonstrated that human 
umbilical cord matrix stem cells provide a significant survival benefit in 
mice with CCl4-induced acute liver failure, through paracrine effects, by 
stimulating endogenous liver regeneration [122].  
Beside liver regeneration, MSC secretome has also been described to 
have anti-fibrotic properties. Li and colleagues demonstrated that 
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transplantation of exosomes derived from human umbilical cord MSC 
could alleviate CCl4-induced liver fibrosis by inhibiting epithelial to 
mesenchymal transition (EMT) and by protecting hepatocytes [123]. 
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CHAPTER 4 
MSC-based therapy for liver fibrosis 
treatment: from in vitro studies to 
clinical trials 
 
Over the past few years, an increasing number of studies have 
evaluated the anti-fibrotic potential of MSCs. In vivo studies highlighted 
the ability of MSCs to reduce liver fibrosis in animal models. In vitro 
studies aimed to elucidate the underlying mechanisms by which MSC 
could modulate HSC activation. Finally, clinical trials evaluate the 
efficiency of MSC transplantation for the treatment of liver fibrosis in 
humans. 
 
4.1. Preclinical studies 
 
Several in vivo studies were performed in order to evaluate the 
therapeutic potential of mesenchymal stem cells in the context of liver 
fibrosis (Table 2) [124] [125] [126] [127] [128] [129] [130] [131] [132]. 
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In most of the studies, liver fibrosis was induced by intraperitoneal or 
subcutaneous injection of CCl4.  This model has the advantage to be the 
best characterized model with respect to histological, biochemical, cell 
and molecular changes associated with the development of liver 
fibrosis. Moreover, it can reproduce the pattern of most of the diseases 
seen in human fibrosis. However, this model has also some limitations 
as it is not a suitable model to study all kinds of liver fibrosis, such as 
biliary fibrosis. Moreover, it cannot provide a perfect simulation of a 
human disease as there are large species differences in immune 
reaction, gene expression/regulation, metabolic, pharmacological and 
tissue response [133]. 
The most studied MSCs are those from the bone marrow. These cells 
have been reported to be beneficial in the prevention of pulmonary 
fibrotic lesions [134]. However, the aspiration of the bone marrow 
remains an invasive procedure. The bleeding tendency of cirrhotic 
patients and their general condition may represent an obstacle for 
autologous cell transplantation.  
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Alternative sources of MSCs such as adipose tissue and umbilical blood 
cord have then been proposed but the number of studies in the context 
of liver fibrosis treatment remains limited, like studies using human 
MSCs in animal models. Most of the cell sources used in the in vivo 
studies are murine MSCs. 
The results of the in vivo studies are promising as they report a 
decrease of the liver fibrosis with a frequent improvement of the 
hepatic functions. Most of the time, these results are observed 4 weeks 
after cell infusion. Long-term studies would be of great interest in order 
to evaluate if the observed anti-fibrotic effect persists over time. 
However, the CCl4 injections need to be continued after the MSC 
injection in order to avoid a regression of liver fibrosis. This represents 
an obstacle to the long-term studies, as animals can hardly support CCl4 
injections during a long period of time. Beside an improvement of liver 
fibrosis and liver function, one study reported also an improvement in 
the liver microcirculation after MSC injection [125]. In two other 
studies, the decrease in the collagen deposition was correlated to a 
decrease of α-SMA expression, a classical marker of activated stellate 
cells [130] [132].  
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In vivo studies highlight the controversy that still remains about the 
exact mechanisms by which MSCs exert their beneficial effect. Indeed, 
some studies mention the differentiation of MSCs into hepatocyte-like 
cells [124] [128] and/ or the expression of metalloproteinases by MSCs 
[128] [129] [132]. The promotion of hepatocyte proliferation and the 
modulation of inflammation have also been proposed [127]. 
The question of the ideal route of MSCs administration remains one of 
the main unsolved issues regarding efficient injection of MSCs. Even if 
the tail vein seems to be the most often used administration route in 
animals, the portal vein [125] [128] and intrahepatic injections [126] 
also seem to be efficient. The optimal doses of cells also need to be 
evaluated as there are significant variations between studies in terms of 
number of cells injected per animal. 
 
4.2. In vitro studies 
 
As mentioned above, following liver injury, hepatic stellate cells (HSC) 
are activated into proliferative, α-smooth muscle actin positive, 
myofibroblast-like and extracellular matrix producing cells [14]. Hence, 
activated HSCs represent an attractive target for antifibrotic therapy.  
62 
 
Several in vitro studies demonstrated the ability of MSCs to modulate 
HSC’s activation indirectly via paracrine mechanisms and directly 
through cell-cell contacts. The use of in vitro models is supported by the 
fact that HSC activation can be mimicked in vitro, when HSCs are in 
contact with the plastic culture dishes [14]. 
 
4.2.1. Paracrine mechanisms 
 
Using indirect co-culture systems, Parekkadan and colleagues showed 
that human bone marrow-derived MSCs were able to inhibit the 
collagen synthesis in rat’s activated HSC and, to a lesser extent, in 
immortalized human HSCs, as demonstrated by a significant reduction 
of procollagen type I C-Peptide secretion level. Moreover, MSCs could 
inhibit HSC’s proliferation and induce their apoptosis, even if HSCs 
didn’t revert to a quiescent state. The underlying mechanisms in the 
modulation of HSC activity by MSCs were attributed to IL-10, TNFα and 
HGF. IL-10 and TNFα secretion by MSCs seemed to inhibit 
synergistically the collagen secretion and the proliferation of HSCs 
while MSC-derived HGF induced apoptosis in activated HSCs, as 
demonstrated by antibody-neutralization studies [135]. 
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Adipose tissue derived human MSCs could also indirectly inhibit murine 
HSC’s proliferation. This growth inhibition is partially mediated by TGF-
β3 and HGF, secreted by MSCs. Neutralization of both cytokines 
synergistically decreased the percentage of cells in the G0/G1 cell cycle 
phase. A decrease in the phosphorylation of extracellular signal-
regulated kinase (ERK) 1/2 by MSCs seemed to be partially involved in 
the suppressive effect of MSCs on HSCs. Gene expression of collagen 
type I and III was also inhibited by MSCs [136]. 
NGF released from human bone marrow-derived MSCs may also 
represent an important paracrine loop by which human HSC’s 
activation can be modulated. Using indirect co-culture systems, Lin and 
colleagues demonstrated that NGF could inhibit HSC’s proliferation and 
promote their apoptosis. The same effect was reproduced using 
recombinant NGF. NF-κB and its target gene, Bcl-xL, seem to take part in 
the regulation of this process [137]. 
 
4.2.2. Cell-cell contacts 
 
Other studies evaluated the effects of direct interplay and juxtacrine 
signaling between MSCs and HSCs. 
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Rat bone marrow-derived MSCs were shown to significantly inhibit rat 
HSCs proliferation and to reduce their α-SMA expression level, through 
a cell-cell contact mode. The Notch pathway, known to induce cell cycle 
arrest, is activated following MSCs-HSCs contact. This signaling 
pathway may take part in the inhibition of HSCs proliferation. In 
addition, the PI3k/Akt pathway seems to be involved in HSC’s growth 
inhibition by the Notch pathway [138]. 
Human bone marrow-derived MSCs were also shown to inhibit the 
proliferation and activation of HSCs (LX-2 cell line) through cell-cell 
contact and through the secretion of HGF. This HSC’s modulation is 
mediated by an inhibition of the TLR4/NF-κB signaling pathway [139]. 
 
Taken together, these studies shed light on new insights regarding the 
mechanisms responsible for the anti-fibrotic effects of MSCs.  
 
4.3. Clinical trials 
 
Over the past few years, nine clinical trials using human MSCs to treat 
patient presenting liver fibrosis have been published (Table 3) [140] 
[141] [142] [143] [144] [145] [146] [147] [148]. 
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The endpoints of the studies were to evaluate the safety and efficacy of 
bone marrow and umbilical cord MSCs transplantation. The cells were 
mostly infused intravenously even if two studies report infusions via 
the hepatic artery [145] [148] and in one study, the cells were even 
injected into the spleen [147]. There is a great variation in the number 
of cells infused per patient and in the frequency of injection in the 
different trials. The results of the studies seem promising in terms of 
improvement of liver function and MELD score. However, there is a lack 
in the evaluation of the liver histology after cell transplantation, except 
in one study reporting histological improvements [148].  
Globally, the size of the samples is small in most studies and there is a 
lack of controls in five studies. The follow up period is quite short, 
except in one study with 192 weeks follow up. We think that it is crucial 
to evaluate the long term efficacy, prognosis and safety before 
proposing this therapy routinely in the clinical practice. 
Using other types of MSCs and other patient populations could also be 
of great interest, in order to evaluate the best therapeutic option for 
each pathology. 
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The use of MSCs in the clinical practice is currently hindered by the 
incapacity to monitor the transplanted cells in the patients and by the 
lack of standardized transplantation protocols. Standardized protocols 
providing informations concerning the timing of cell injection following 
the stage of liver fibrosis, the number of cells and the administration 
route would be useful. 
 Only randomized controlled clinical trials are able to assess the 
potential clinical benefit of MSCs for patients affected by liver fibrosis. 
According to the clinical trials Website of the United States sponsored 
by the National Institutes of Health (http://clinicaltrials.gov), 
approximately 24 clinical trials are currently ongoing. 
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CHAPTER 5 
Future prospects 
 
MSCs may represent a clinical relevant solution for the treatment of 
liver fibrosis, given their interesting properties and the promising 
results of the preclinical and clinical studies.  
However, several issues need to be clarified before MSC can be 
routinely proposed as a therapeutic option to treat liver fibrosis.  
Over the past few years, concerns have been raised about the long-term 
effectiveness of MSCs cell-based therapy and the potential tumorigenic 
risk. Several evidences suggest that MSCs might promote tumor growth 
in vivo [149] [150] [151]. On the other hand, thanks to their 
immunomodulatory properties, MSCs may have an antitumor effect, in 
relation with the modulation of the inflammatory environment that 
characterizes many tumors [152] [153] [154]. MSCs are also able to 
interact with cancer cells and to inhibit signaling pathways associated 
with tumor growth and cell division [155] [156]. 
Moreover, there is a lack of standardized protocols for MSC 
transplantation. The optimal MSC doses, the timing and frequency of 
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injection and the administration route differ considerably between the 
different studies.  
For all these reasons, we think that further studies, and in particular 
randomized controlled trials, are needed in order to evaluate the long 
term safety and efficacy of MSC-based treatment. Moreover, potency 
tests performed on MSCs before the injection to patients could be 
useful. 
 
Conclusion 
 
Although considerable advances have been made in the past decade to 
better understand the cellular and molecular mechanisms underlying 
liver fibrogenesis, no efficient therapy is available so far to treat this 
serious condition. 
Further investigations and efforts are currently conducted to efficiently 
reverse liver fibrosis. MSC-based therapy has been shown to have a 
significant potential to decrease mortality and to improve the quality of 
life of patients suffering from liver fibrosis. A standardization is 
however needed before proposing this strategy routinely in clinical 
practice.   
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As described in the introduction, liver fibrosis is a worldwide health 
problem. Except orthotopic liver transplantation, no effective treatment 
is available so far. Organ shortage being an increasing daily reality, 
there is an urgent need to find alternative therapeutic strategies. 
The most promising emerging strategy seems to be cell based therapy 
and in particular mesenchymal stem cells. 
Adult-Derived Human Liver Stem/progenitor Cells (ADHLSCs) share 
similar characteristics with extra-hepatic MSCs but are more closely 
related to the liver. 
The objective of the current work is to evaluate the anti-fibrotic 
properties of ADHLSCs by studying their interactions with human 
hepatic stellate cells (HSCs), the main cell type implicated in the 
extracellular matrix production. 
To address this issue, our first aim was to find tools that could allow the 
discrimination between ADHLSCs and HSCs.  
Thereafter, our second aim was to evaluate the ability of ADHLSCs to 
modulate HSC activation process in vitro. 
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Paper 1 
Gene expression profiling and secretome analysis 
differentiate Adult-Derived Human Liver 
Stem/progenitor Cells and human hepatic stellate 
cells. 
 
Berardis Silvia, Lombard Catherine, Evraerts Jonathan, El Taghdouini 
Adil, Rosseels Valérie, Sancho-Bru Pau, Lozano Juan Jose, van Grunsven 
Leo, Sokal Etienne Marc, Najimi Mustapha.  PLoS One 2014;9:e86137. 
 
 
The first part of this thesis work focuses on an in-depth comparative 
analysis of both Adult-Derived Human Liver Stem/progenitor Cells 
(ADHLSCs) and human hepatic stellate cells (HSCs). Indeed, the two cell 
types that were investigated in the current study are derived from the 
adult human liver and present numerous similar characteristics, 
including their morphology. The aim of this study is to assess the tools 
that may help to accurately discriminate both cell types and confirm 
their singularity before analyzing the study of their interactions. 
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In this work, we demonstrated that the studied cell populations present 
distinct gene expression and secretome profiles. Of importance, we also 
noticed that ADHLSCs secrete molecules of therapeutic and 
immunomodulatory importance that may support the anti-fibrotic 
effect of ADHLSCs. 
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Abstract  
 
Adult-derived human liver stem/progenitor cells (ADHLSC) are 
obtained after primary culture of the liver parenchymal fraction. The 
cells are of fibroblastic morphology and exhibit a hepato-mesenchymal 
phenotype. Hepatic stellate cells (HSC) derived from the liver non-
parenchymal fraction, present a comparable morphology as ADHLSC. 
Because both ADHLSC and HSC are described as liver stem/progenitor 
cells, we strived to extensively compare both cell populations at 
different levels and to propose tools demonstrating their singularity.  
ADHLSC and HSC were isolated from the liver of four different donors, 
expanded in vitro and followed from passage 5 until passage 11. Cell 
characterization was performed using immunocytochemistry, western 
blotting, flow cytometry, and gene microarray analyses. The secretion 
profile of the cells was evaluated using Elisa and multiplex Luminex 
assays.  
Both cell types expressed α-smooth muscle actin, vimentin, fibronectin, 
CD73 and CD90 in accordance with their mesenchymal origin. 
Microarray analysis revealed significant differences in gene expression 
profiles. HSC present high expression levels of neuronal markers as well 
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as cytokeratins. Such differences were confirmed using 
immunocytochemistry and western blotting assays. Furthermore, both 
cell types displayed distinct secretion profiles as ADHLSC highly 
secreted cytokines of therapeutic and immuno-modulatory importance, 
like HGF, interferon-ɤ and IL-10.  
Our study demonstrates that ADHLSC and HSC are distinct liver 
fibroblastic cell populations exhibiting significant different expression 
and secretion profiles.  
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Introduction 
 
The liver is composed of parenchymal and non-parenchymal cell 
populations. Complex and well-organized interactions between such 
cell types allow a perfect coordination of the liver functions for 
preservation of the systemic homeostasis. Indeed, the liver is 
concomitantly managing numerous important functions such as 
metabolism, protein synthesis and detoxification. Hepatocytes are the 
main parenchymal cell type and represent the most important 
functional one. Liver non-parenchymal cells include epithelial bile duct 
cells, non-epithelial Kupffer cells, sinusoidal endothelial cells and 
hepatic stellate cells (HSCs) [1]. 
Spindle shaped HSCs are located in the space of Disse between 
hepatocytes and sinusoidal endothelial cells [2]. The HSC population 
represents about 15% of the total number of resident cells in the 
normal liver. These cells have several important functions including 
retinyl ester storage and homeostasis, remodeling of extracellular 
matrix, production of growth factors and cytokines, contraction and 
dilatation of the sinusoidal lumen [3]. During liver injury, HSC are 
“activated” and evolve to myofibroblast-like cells. This activation is 
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characterized by an increase in cell proliferation and extracellular 
matrix protein deposition. At the structural level, activated HSC lose 
their big Vitamin A-containing lipid droplets and up-regulate the 
expression of some cell adhesion molecules like ICAM-1, VCAM-1 and 
NCAM and of α-smooth muscle actin as well as the secretion of pro-
inflammatory cytokines [4] [5]. In vitro, part of this activation process is 
mimicked by culturing the cells on plastic culture dishes [6].  
Our group previously obtained stem/progenitor cells from healthy 
adult human liver (ADHLSC). These expandable cells present a hepato-
mesenchymal phenotype and have the potential to differentiate into 
hepatocyte-like cells both in vitro and in vivo [7] [8] [9]. Cultured 
ADHLSC exhibit a striking phenotypical resemblance with culture 
activated HSCs. Moreover, alike ADHLSCs, quiescent HSCs have been 
reported to express molecular markers of stem/progenitor cells and to 
be involved in liver regeneration [7] [10] [11].  
In the current study, we carried out an extensive comparison between 
HSCs and ADHLSCs in order to assess the unique identity of ADHLSCs 
and to identify tools that can be used to differentiate both populations. 
To this end, we compared these mesenchymal cells after isolation from 
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the same liver by following their phenotype, genotype and behavior in 
vitro from passage 5 until passage 11.  
We report several characteristics similar to both cell types but shed 
light on significant gene expression profile and functional differences. 
This study confirms the unique characteristics of ADHLSCs and 
demonstrates their secretion potential of cytokines that could be of 
therapeutic and immuno-modulatory importance.  
 
Materials and methods 
 
ADHLSC and HSC isolation and culture 
The protocol and experiments were approved by the ethical 
committees of the St-Luc Hospital and faculty of Medicine of Université 
Catholique de Louvain. An agreement from the Belgian Ministry of 
Health was obtained for the Hepatocytes and Hepatic Stem Cells Bank. A 
written and signed informed consent has been obtained for each human 
liver used in the current study. 
Four donors were used in the current study (Table 1).  
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Table 1: Characteristics of the four liver donors from which HSC and ADHLSC were 
isolated  
Donor 
number 
Age Gende
r 
Reason of 
death 
Blood 
group 
Ischemia 
time 
89 3 days M Respiratory A+ 4 hours 
93 2 years F Metabolic 
disease (liver 
transplanted) 
O+ 1 hour 43 
97 7 
months 
F Meningitis A+ 5 hours 30 
98 7 days M Cardio-
respiratory 
arrest 
O- 4 hours 20 
 
ADHLSC were obtained subsequently to primary culture of the liver 
parenchymal fraction previously obtained after a two-step collagenase 
perfusion, filtration and low speed centrifugation [7]. HSCs were 
isolated from the corresponding non-parenchymal fraction using a 
Nycodenz gradient centrifugation step (Myegaard, Oslo, Norway) [12]. 
Both cell types were cultured using DMEM containing 4.5g/L glucose 
(Invitrogen) supplemented with 10% Fetal Calf Serum (PAA) and 1% 
Penicillin/Streptomycin (Invitrogen), at 37°C in a fully humidified 
atmosphere (5% CO2). When reaching 80% confluence, cells were lifted 
with 0.05% trypsin-EDTA (Invitrogen) and replated at a density of 
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5000 cells/cm². The viability of recovered cells was evaluated using 
trypan blue exclusion assay. 
  
Immuno-cytochemistry 
Cells were fixed using paraformaldehyde 3.5%, for 15 min at room 
temperature. Endogenous peroxidase was eliminated using hydrogen 
peroxide 3.3% for 3 minutes. All steps were performed at room 
temperature. Cells were permeabilized using D-PBS containing 1% 
Triton X-100 (Sigma) for 10 minutes. Non-specific immuno-staining 
was prevented by 1h incubation in D-PBS containing 1% Bovine Serum 
Albumin (Sigma). Thereafter, cells were incubated with primary 
antibody for 1h (Table 2).  
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Table 2: Primary antibodies used for the phenotypic characterization of ADHLSC and 
HSC by immunocytochemistry & western blotting  
Antibody Supplier Reference Concentration 
used 
ASMA Dako M0851 1/100 
CK-18 Dako M7010 1/350 
CK-19 Dako M0888 1/350 
Desmin Abcam Ab6322 1/50 
Fibronectin Abcam Ab32419 1/100 
NCAM Abcam Ab9018 1/100 
Nestin Abcam Ab22035 1/1000 
Vimentin Progen 105-15 1/100 
 
 
After washing, cells were incubated with secondary antibody (EnVision 
– Dako) during 30 minutes. Detection was performed after 5 minutes 
incubation with liquid DAB and substrate chromogen (Dako). 
Counterstaining was performed using Mayer’s hematoxylin for 10 
minutes. Preparations were then mounted for microscopic analysis 
(DMIL, Leica, Belgium).  
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Western Blotting 
Extracted Protein concentrations were determined using the BCA 
protein assay kit (Thermo Scientific). Fifty micrograms of protein 
samples were boiled for 10 min at 100°C and prepared for loading by 
adding dithiotreitol and bromophenol blue. Cell lysates were separated 
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
electroblotted onto polyvinylidene difluoride membranes. Blots were 
blocked with 5% milk powder in TBS with 0,2% tween (TBS-T). 
Following a washing step with TBS-T, membranes were incubated 
overnight with following primary antibodies and dilutions: CK18 (1:350 
[DAKO]), CK19 (1:350 [DAKO]). Antibodies were diluted in blocking 
buffer. After additional TBS-T washes, membranes were incubated with 
secondary antibody for 1h (dilution: 1/20.000). The antigens were 
detected by enhanced chemiluminescence using ECL substrate.  
 
Gene expression profile analysis 
RNA was quantified with a Nanodrop1000 (Thermo Scientific) and RNA 
integrity evaluated with a Bioanalyzer 2100 (Agilent Technologies). 
500pg-50ng total RNA were amplified with an Ovation Pico SL V2 Kit 
(NuGENE) and labelled with an Encore Biotin Module (NuGENE) 
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following standard procedures. HG-U219 plates were hybridized with 
an automated array processing GeneTitan (Affymetrix). 
Affymetrix gene expression data were normalized using the robust 
multi-array algorithm [13] using a custom probe set definition that 
mapped probes to 18567 Entrez Gene Ids (HGU219_Hs_ENTREZG) [14]. 
Genes with a coefficient of variation lower than 0.03 were eliminated, 
resulting in a set of 13925 genes.  
For the detection of differentially expressed genes, a linear model was 
fitted to the data and empirical Bayes moderated statistics were 
calculated using the limma package from Bioconductor [15]. 
Adjustment of p-values was done by the determination of false 
discovery rates (FDR) using the Benjamini-Hochberg procedure [15]. 
Genes representing a change of 1.5-fold or greater and moderated p-
value <0.05 were considered as differentially expressed. 
Functional analysis of gene expression data was conducted using the 
R/Bioconductor package GOstats and the GO database 
(http://www.geneontology.org). Only genes that could be associated 
with a unique Entrez Gene ID were used. Among those, only the genes 
representing a fold change of 1.5 or greater and a moderated p-
value<0,05 were selected. The hypergeometric distribution was used to 
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evaluate the probability of randomly observing the enrichment for each 
GO term [16]. The data are deposited at Gene Expression Omnibus 
under reference number GSE49995. 
Gene Set Enrichment Analysis (GSEA) was employed to identify 
biological pathways significantly associated with the ADHLSC. In 
comparison to other strategies for analysis of molecular profiling data 
that focus on high scoring individual genes, GSEA does not employ a 
significance threshold and evaluates microarray data at the level of 
gene sets defined based on prior biological knowledge. This approach 
has been reported to yield robust results even when dealing with 
heterogeneous samples with subtle sample class differences. For the 
current analysis, gene sets were extracted from the full Molecular 
Signature Database (MSigDB v.4-0). Additionally the subset of canonical 
pathway is analyzed alone.  Analyses were based on a Signal2noise 
metric and a weighted scoring scheme with 1000 permutations on gene 
sets. Only gene sets with more than 15 genes were included in the 
analysis. 
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RT-qPCR 
Total RNA was extracted from 1.5 million cells for each cell population 
using Tripure isolation reagent (Roche). cDNA was generated from 1µg 
of RNA using the ThermoscriptTM RT kit (Invitrogen) according to 
manufacturer’s instructions. qPCR was carried out in duplicate using 
TaqMan Gene expression Master Mix (Applied Biosystems) and pre-
designed TaqMan probes and primers obtained from Applied 
Biosystems. The amplification was performed using the StepOnePlus 
Real-time PCR machine. The housekeeping gene cyclophilin A (PPIA) 
was used as a reference gene for normalization and water was used as a 
negative control.   
 
Flow cytometry 
Cells were re-suspended in D-PBS at a concentration of 2x105 cells /ml. 
For intracellular immunostaining, cell permeabilization was performed 
with cytofix/cytoperm for 20 minutes at 4°C (BD Pharmingen). Cells 
were then washed and incubated for 30 minutes at 4°C with the 
antibodies (see Table 3).  
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Table 3:  Antibodies used for the phenotypic characterization of ADHLSCs and HSCs 
by flow cytometry 
Antibody Fluorochrome Corresponding isotype Supplier Reference Concentration  
Anti-ASMA FITC MsIgG2a Abcam Ab8211 1/10 
Anti-CD29 APC MsIgG1, k BD 559883 1/10 
Anti-CD44 FITC MsIgG2b, k BD 555478 1/10 
Anti-CD45 PE-Cy7 MsIgG1, k BD 557748 1/10 
Anti-CD73 PE MsIgG1, k BD 550257 1/10 
Anti-CD90 APC MsIgG1, k BD 559869 1/10 
Anti-CD117 APC MsIgG1, k BD 550412 1/10 
Anti-
CD133/2 
PE MsIgG1 Milten
yi 
130-080-901 1/5 
 
 
The corresponding control isotypes were used to evaluate the non-
specific binding. After washing, cells were suspended in Stabilizing 
Fixative (BD Pharmingen) before reading with a CANTO II flow 
cytometer. The analyses were performed using the BD FACSDiva 
Software. 
  
ELISA 
When 60-70% of confluence was reached, the cells were washed and 
the conditioned medium was replaced by a serum-free medium. After 
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24 hours incubation, supernatants were collected and cells were lifted 
for counting and viability evaluation using trypan blue exclusion assay. 
For the collagen secretion analysis, we used an Elisa kit for the 
procollagen type I C-Peptide (Takara Bio Inc, Japan). Hepatocyte 
Growth Factor (HGF) and Transforming Growth Factor beta 1 (TGFβ1) 
levels in the culture supernatants were assayed by using Quantikine 
Elisa Kits from R&D Systems. The experiments were performed 
according to the manufacturer’s instructions. For TGFβ1 Elisa, samples 
were activated by acidification followed by neutralization in order to 
activate latent TGFβ1 to immune-reactive TGFβ1 detectable by the 
Quantikine TGFβ1 immunoassay. The measurement of the absorbance 
at 450 nm was done with a Victor X4 plate Reader (PerkinElmer). For 
HGF and TGFβ1 kits, a reading at 570 nm was subtracted to the 450 nm 
reading to correct the optical imperfections of the plates. 
 
Luminex analysis 
We also used a 27plex kit (IL-1b, IP-10, IL-2, IL-4, IL-6, IL-7, IL-9, IL-10, 
IL-13, IL-15, Eotaxin, FGF, GM-CSF, INF-ɤ, MIP-1a, MIP-1b, RANTES, 
TNFα, IL-1ra, IL-5, IL-8, IL-12, IL-17, G-CSF, MCP-1, PDGF-bb and VEGF) 
and the Luminex technology (Bio-Plex 200, Biorad) to investigate the 
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secretome of both liver cell types . The principle of the technique is 
based on color-coded beads and enables to detect up to 100 cytokines 
simultaneously. The primary antibody directed against the target 
protein is conjugated with the dyed beads. After several washes to 
remove unbounded proteins, a secondary biotinylated antibody is 
added to the reaction. Streptavidin-phycoerythrin (Streptavidin-PE) is 
then added to bind the biotinylated antibody. By measuring the relative 
fluorescence intensity, the antigen-antibody reaction can be measured. 
The assays were performed following the manufacturer’s instructions. 
Briefly, after the pre-wetting of the plate, 50µl of the beads were added 
in each well and washed twice. 50 µl of the samples (serum free culture 
supernatants recovered after 24 hours of culture) were added to the 
plate. The plate was shaken during 30 seconds and then incubated for 
45 minutes on a plate shaker at 120 rpm at room temperature. The 
plate was washed three times with the Bio-Plex wash buffer and 25µl of 
the detection antibody was added in each well and incubated for 30 
minutes on a plate shaker at 120 rpm. The plate was then washed three 
times with the Bio-Plex wash buffer and 50 µl of the Streptavidin-PE 
solution was added in each well. The plate was shaken during 30 
seconds and incubated for 10 minutes on a plate shaker at 120 rpm. 
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Finally, after three washes of the plate with the Bio-Plex wash buffer, 
the beads were resuspended with 125µl of Bio-Plex Assay Buffer. The 
plate was read by the Luminex machine and the data were analyzed 
using Bio-Plex Manager 6.0. 
 
 
Statistics 
Results, others than those of microarray studies, are expressed as mean 
± standard error of the mean (SEM). Statistical differences were 
determined by Student's t test for two groups’ comparison. Differences 
were considered significant when p values *p<0.05, **p<0.01, 
***p<0.001. 
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Results 
 
Phenotypic and genotypic characterization of ADHLSC and HSC 
For each liver donor, HSC and ADHLSC were cultivated under the same 
culture conditions and concomitantly followed. The fibroblastic 
morphology displayed by both cell types remained stable over the 
different studied passages (Figure 1A). The population cumulative 
doubling was similar for the two cell types (Figure 1B).  
 
Figure 1. ADHLSC and HSC in culture. A, Fibroblastic morphology at passages 5 & 9 
as shown using phase contrast microscopy, original magnification 100x. B, Cumulative 
population doubling of both cell types from passage 5 to passage 11 (n=4). 
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We investigated the mesenchymal phenotype of both cell types (n=4) 
by exploring the expression of several specific appropriate markers 
using flow cytometry. Both cell types were immuno-positive for most of 
the membrane markers widely used to characterize mesenchymal stem 
cells. This was the case for CD73, CD90, CD29, and CD44 for which 
expression levels remained stable for the analyzed passages (Table 4).  
 
Table 4 : Phenotypic characterization of ADHLSC and HSC by flow cytometry for 
mesenchymal stem cells, hematopoietic cells and extracellular matrix markers. Data 
presented as mean percentage of immunopositive cells from four different donors at 
early (P5) and late(P11) passages. No significant difference was observed between the 
two cell populations. 
  
 
                            ADHLSC                         HSC 
        P5 P11   P5 P11 
Mesenchymal stem cells markers 
      
   
ASMA 87,8 + 4,7% 83,8 + 2,9% 
 
91,9 + 5,5% 87,4 + 12,6% 
   
CD73 88,2 + 5,9% 90,2 + 6,1% 
 
89,9 + 2,5% 82,8 + 20,1% 
      CD90 97,2 + 2,7% 92,7 + 7,8%   95,6 + 2,3% 88,7 + 10,4% 
         
Hematopoietic cells markers 
      
   
CD133 0,7 + 0,2% 1,3 + 0,3% 
 
2,1 + 2,2% 2,2 + 2,3% 
   
CD45 1,4 + 0,8% 2,6 + 3,1% 
 
1,7 + 1,0% 1,8 + 1,9% 
      CD117 0 + 0% 0,07 + 0,12%   0,3 + 0,4% 0,03 + 0,06% 
         
Extracellular matrix markers 
      
   
CD49b 95,6 + 1,1% 95,5 + 2% 
 
89,7 + 8,0% 90 + 9,7% 
   
CD29 86,4 + 10,2% 60,8 + 11% 
 
77 + 21,5% 56,6 + 49,64% 
      CD44 77,5 + 8,6% 79,7 + 9,2%   68 + 4,1% 75 + 18,9% 
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No significant difference was noticed between HSC and ADHLSC. These 
findings were confirmed using immunocytochemistry and RT-qPCR 
after analyzing the expression of other classical mesenchymal markers 
like vimentin, α-smooth muscle actin and fibronectin (data not shown). 
The mesenchymal phenotype of both cell types was also supported by 
the negative expression of hematopoietic markers like CD45, CD117 
and CD133 as demonstrated using flow cytometry (Table 4).  
This first comparative characterization only confirmed the 
mesenchymal phenotype of ADHLSCs and HSCs but did not allow us to 
discriminate both cell populations. We thereafter studied the gene 
expression profile of ADHLSCs and HSCs using Affymetrix HG-U219 
gene chips expression. The analysis was performed on 7 different 
samples for each cell population (4 samples from the four donors at 
Passage 5 + 3 samples from only 3 donors at Passage 7). These 
experiments allowed us to point out significant signature differences 
(100 top genes that are significantly differentially expressed in the two 
cell populations) after screening of 13925 genes (Figure 2A). We 
noticed that liver stem/progenitor cells highly and predominantly 
expressed chemokine ligands such as CXCL1, CXCL3, CXCL5, CXCL6 and 
CXCL7 when compared to HSCs (Figure 2B). ADHLSCs also displayed 
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increased levels of cytokines like IL-1β, IL-6, IL-8, IL-33, and LIF as well 
as of growth factors like HGF in comparison with HSC (Figure 2B).  
 
 
Figure 2. Gene expression profile analysis of ADHLSC and HSC using 
microarrays. A, Hundred top genes significantly and differentially expressed in the 
two cell populations (4 samples from passage 5 for all donors and 3 samples at 
passage 7 for 3 donors including the diseased donor). Red bars denote over-
expression, black bars denote equally expression and green bars denote under-
expression. B, chemokines and cytokines expression profile. 
 
 
Regarding cytoplasmic markers, HSCs expressed significantly higher 
amounts of desmin (type III intermediate filament), elastin, 
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desmoplakin (anchors intermediate filaments to desmosomal plaques) 
and dystrophin as compared to ADHLSC (Figure 2C). 
When comparing MMP expression between the two cell types, we 
noticed an elevated expression of MMP2, MMP3 and MMP14 in 
ADHLSCs and an increased expression of MMP16 in HSCs (Figure 2C).  
 
 
Figure 2. Gene expression profile analysis of ADHLSC and HSC using 
microarrays. 
C, intracytoplasmic, intermediate filaments, and neural growth factors.  
 
In order to obtain a functional annotation of our gene expression 
results, we used the Gene Set Enrichment Analysis (GSEA) method. We 
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have used GSEA to identify those most relevant “canonical” pathways 
and Gene ontology categories enriched in ADHLSC. Results are included 
in Figure 2D and Table 5. 
 
 
Figure 2. Gene expression profile analysis of ADHLSC and HSC using 
microarrays. D, Gene Set Enrichment Analysis (GSEA). Selected statistically 
significant GSEA plots obtained from enriched ADHLSC. Within these plots, the green 
line represents the sliding enrichment score and the black bars demarcate the 
position of the gene set members within the ranked expression data.  
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Table 5 : Gene Set Enrichment Analysis biological: Pathways significantly associated 
with ADHLSC and the corresponding FDR as well as the enriched genes 
 
GENESET SIZE FDR_P 
VALUE 
ENRICHED GENES 
KEGG_CYTOKINE_CYTOK
INE_RECEPTOR_INTERAC
TION  
213 0,000 CXCL5 CXCL1 CSF3 IL1B CXCL3 
CXCL6 BMP2 IL8 CCL7 HGF CSF2 
IL11 CCL20 LIF CCL11 TGFB1 
TNFRSF19 CXCL2 IL24 IL1A CCL5 
TNFRSF21 CCL8 CLCF1 EPOR CRLF2 
IL19 IL15RA CCL24 TNFRSF10A 
RELT CNTFR FLT3 TNFRSF12A 
TGFB2 IL17RA CSF1 TNFRSF1A 
VEGFA CXCR3 AMHR2 AMH 
TNFRSF10B CCL23 CCL2 TGFBR2 
TNFRSF1B CCL26 IL6 CCL3 IL7R 
CCR9 LTB IL18R1 TNFSF15 IL17RB 
EPO NGFR CCL4 CD40 TNFSF4 
CXCL10 PDGFB IL10RB TNFSF8 
CX3CL1 ACVR1B CD27 IL2RG 
TNFRSF8 FLT4 IFNE TNFSF14 
TNFRSF10C CCR7  
REACTOME_CHEMOKINE
_RECEPTORS_BIND_CHE
MOKINES  
46 0,000 CXCL5 CXCL1 CXCL3 CXCL6 IL8 
CCL7 CCL20 CCL11 CXCL2 CCL5  
KEGG_CHEMOKINE_SIGN
ALING_PATHWAY  
135 0,002 CXCL5 CXCL1 CXCL3 CXCL6 IL8 
CCL7 CCL20 GNB2 CCL11 RAC2 
CXCL2 CCL5 CCL8 PRKX PIK3CD 
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TIAM2 SHC1 CCL24 GNAI2 PIK3R2 
PREX1 CXCR3 BCAR1 NFKBIA CCL23 
CCL2 CCL26 GNG2 NFKBIB CCL3 
CCR9 PRKACA IKBKG CSK ADRBK1 
CCL4 PXN PRKCZ CXCL10 STAT2 
CX3CL1  
REACTOME_SIGNALING_
BY_ILS  
70 0,041 IL1B IRAK3 HGF CSF2 IL1A PIK3CD 
SOCS3 SHC1 NFKB2 IRAK2 TAB1 
PIK3R2 CASP1 GAB2 PELI3 IL6 IL7R 
IKBKG MYD88 IRAK1 SQSTM1 
PELI2 MAP2K4 NOD2 IL2RG  
PID_LYSOPHOSPHOLIPID
_PATHWAY  
51 0,028 IL8 GNA11 TRIP6 GNAI2 MMP2 
ARHGEF1 BCAR1 NFKBIA PLCG1 
GNG2 IL6 HBEGF FOS GNAZ JUN 
ADRA1B PRKCE PXN GNA12 PLD2 
ADCY5  
REACTOME_AMYLOIDS  59 0,009 HIST1H3I HIST1H2BM HIST1H2BN 
CST3 HIST1H4K HIST4H4 HIST1H3F 
HIST1H2BL SNCA HIST1H3B 
HIST1H2BF HIST1H3A HIST3H2BB 
HIST1H2BH HIST1H2BG HIST2H2BE 
HIST1H4L HIST1H3D HIST1H2BC 
HIST1H4D HIST1H3E HIST1H3G 
HIST1H3J HIST1H2BE HIST1H2BO 
HIST1H2AJ HIST1H2BI HIST1H4B 
HIST1H4H MFGE8  
VILIMAS_NOTCH1_TARG
ETS_UP  
40 0,001 BCL2A1 ICAM1 CCL5 HEY1 JUNB 
EGR1 NFKB2 THY1 EGR2 RELB 
BIRC3 DTX1 CARD11 NFKBIA ZAP70 
P2RY10  
PHONG_TNF_TARGETS_
UP  
56 0,000 CXCL1 CXCL3 BMP2 IL8 CSF2 IL11 
CCL20 LIF ICAM1 CXCL2 ETS2 PLAU 
IER2 LDLR TNFAIP3 IRF1 BTG1 
JUNB EGR1 NFKB2 NKX3-1 ATF3 
EGR2 BIRC3 DUSP1 NFKBIA 
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TNFRSF10B REL IL6 FOS SDC4 JUN 
MCL1  
CHR22Q12  74 0,000 TBC1D10A RAC2 APOL2 SMTN 
HMOX1 PES1 SUN2 MAFF SELM 
EMID1 PIK3IP1 TOB2 CSNK1E 
GATSL3 CBX6 PISD SEC14L2 MYH9 
SLC16A8 GAS2L1 GALR3 PDXP 
APOL5 CACNA1I TOMM22 RBFOX2 
PVALB ASCC2 CYTH4 MTMR3 SYN3 
HORMAD2 SLC5A4 PDGFB CHEK2 
OSBP2 DMC1 APOL6 KREMEN1  
CYTOKINE_ACTIVITY  94 0,000 CXCL5 CXCL1 CSF3 CXCL3 CXCL6 
IL8 CCL7 CSF2 CCL20 CCL11 CXCL2 
CCL5 CCL8 GDF15 NAMPT IL19 
TRIP6 CCL24 CDK5 TGFB2 CSF1 
VEGFA MIF CCL23 CCL2  
 
 
Interestingly, HSCs exhibited significantly higher levels of neuronal 
markers such as NGF, neurotrophin 3, NDNF, and NEDD 2 & 9 than 
ADHLSCs (Figure 2C).  
 
 
Such significant differences were also confirmed using immuno-
cytochemistry. Indeed, we observed that NCAM is expressed in HSC but 
not in ADHLSC; a difference stably maintained over the passages 
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(Figure 3A). Nestin and Desmin expression was predominant in HSCs as 
compared to ADHLSC (Figure 3A). 
HSC but not ADHLSC expressed hepatic cytokeratins like cytokeratin 18 
and cytokeratin 19 at the protein level, as demonstrated using western 
blotting (Figure 3B).  
 
 
 
Figure 3. Immunodetection comparative study. A, HSCs show a positive 
immunostaining for neural markers like NCAM and nestin and for desmin. The 
expression level of nestin and desmin is higher in HSC in comparison with ADHLSC. 
ADHLSC do not express NCAM at the protein level. Images are representative of 
several fields examined from four different donors. Magnification 400x. B, Total 
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proteins were extracted from ADHLSC and HSC and CK-18 and CK-19 immuno-
detection was realized using western blotting. Data shown are representative of 4 
different cell samples isolated from 4 different donors. 
 
 
These observations are in accordance with the microarray analyses that 
revealed a higher expression level of keratins 7, 14, 18, 19, & 34 by HSC 
when compared to ADHLSCs (Figure 2C).  
All together, these findings clearly show that cultured HSCs and 
ADHLSCs are two different cell populations with distinct gene 
expression profiles. 
 
Functional characterization of ADHLSCs and HSCs – Cytokines and 
growth factors secretion 
After phenotypic and genotypic characterization, we carried out a 
functional analysis of both cell populations by assessing their secretome 
profile in the corresponding conditioned culture medium of cells 
originated from 3 different donors at passages 5 &7. This was 
performed on supernatants collected 24 hours after incubation with 
serum free medium. As collagen is known to be secreted by activated 
HSCs, we evaluated its secretion by measuring the pro-collagen type-I 
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C-Peptide in the culture supernatants. No significant difference was 
observed between HSCs and ADHLSCs (Figure 4A). We thereafter 
looked at some markers known to play important functional roles in 
terms of immuno-modulation and liver regeneration. Secretion of 
Transforming growth factor-beta 1 (TGF-β1), one of the most powerful 
pro-fibrotic cytokines and involved in inflammatory and immune 
responses, was confirmed in our activated human hepatic stellate cell 
cultures. We demonstrated that ADHLSCs secrete equivalent amounts 
of TGFβ1 in the culture supernatant (Figure 4B). 
HGF is a hepatocyte mitogen, which has several crucial physiological 
functions including organ protection and regeneration. Following liver 
injury, HGF is known to be secreted by distant organs such as spleen, 
lungs and kidneys as well as by sinusoidal cells such as Kupffer cells 
and HSCs. Moreover, HGF has anti-inflammatory properties. We 
observed a significant difference in HGF production between HSCs and 
ADHLSCs. The liver stem/progenitor cells seemed to secrete HGF about 
three times more than HSCs (Figure 4C). 
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Figure 4. Secretome profile in the conditioned culture medium of ADHLSC and 
HSC. The Elisa analyses were performed on supernatants (n=3 including the diseased 
donor, analyzed at passage 5 and passage 7) collected 24 hours after incubation with 
serum free medium. A, the collagen secretion was evaluated by measuring the 
procollagen type-I C-Peptide, precursor of the collagen type I, by Elisa. No significant 
difference was observed between HSC and ADHLSC. B, TGFβ1 secretion; ADHLSC and 
HSC secrete an equivalent amount of TGFβ1 in the culture supernatant. C, HGF 
secretion; we observed a significant difference in HGF secretion between HSC and 
ADHLSC. The liver stem/progenitor cells seem to secrete HGF about three times more 
than HSC.  
 
 
In the second part of this functional analysis, we focused on cytokines 
implicated in the inflammatory response. Indeed, HSC are known to 
secrete several pro-inflammatory cytokines while ADHLSC seem to 
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exhibit immuno-modulatory properties. Twenty-seven cytokines were 
analyzed, using a multiplex technology. The cytokines were classified as 
growth factors, chemokines, pro-inflammatory cytokines, anti-
inflammatory cytokines and those with dual roles. Among the growth 
factors analyzed, the main differences were noticed for VEGF and 
PDGFbb for which significant higher levels were detected in ADHLSCs 
(Figure 5A). The increase in VEGF and PDGFbb levels was respectively 
17 and 1.5 times as compared to HSCs from the same donor. Regarding 
the chemokines analyzed, Eotaxin (CCL11) was 14 times more secreted 
by ADHLSC than HSC (Figure 5A). With respect to pro-inflammatory 
cytokines, the major differences between the two cell populations were 
IP-10 (3.6 times), IL-5 (2 times), IL-7 (2 times), IL-8 (30 times), and IL-
17 (4.5 times), which are highly secreted by ADHLSC. To a lesser extent, 
the same trend was observed for IL-9 (1.6 times), IL-12 (1.7 times), 
interferonɤ (1.5 times) and TNFα (1.6 times) (Figures 5A & 5B). 
Concerning the anti-inflammatory cytokines, a significant higher level 
of IL-13 (2.1 times) and IL-10 (1.8 times), was secreted by ADHLSCs as 
compared to HSCs. IL-1ra, a natural inhibitor of the pro-inflammatory 
effect of IL1β, and IL-4 (presenting anti- and pro-inflammatory 
properties) were also produced in higher concentrations by ADHLSCs, 
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even if the statistical difference was less important (Figure 5B). IL-2 is 
considered to play a dual role as it has pro- and anti-inflammatory 
activities. The concentration of this cytokine was found to be higher in 
the culture supernatant of ADHLSCs (1.5 times) in comparison with the 
one of HSCs (Figure 5B). 
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Figure 5. Secretome analysis of ADHLSC and HSC using a multiplex technology 
(Luminex). The analyses were performed on culture supernatants collected 24 hours 
after incubation with serum free medium (n=3, from 2 healthy and 1 diseased donors; 
analyzed at passage 5 and passage 7). The growth factors and cytokines 
concentrations were calculated for 100 000 cells. A, ADHLSC secrete high levels of 
VEGF, PDGFbb and Eotaxin as compared to HSC. *** denotes a p value <0,001; ** 
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denotes a p value < 0,01; * denotes a p value < 0,05. NS: Not significant. B, concerning 
pro-inflammatory cytokines, ADHLSC highly secreted IP-10 (3.6 times), IL-5 (2 times), 
IL-7 (2 times), IL-8 (30 times), and IL-17 (4.5 times) as compared to HSC. With respect 
to anti-inflammatory cytokines, ADHLSC significantly secreted higher level of IL-13 
(2.1 times) and IL-10 (1.8 times). *** denotes a p value <0,001; ** denotes a p value < 
0,01; * denotes a p value < 0,05. NS: Not significant. 
These findings confirm the singularity of both cell populations and 
support the expression profile differences demonstrated using gene 
expression analyses. 
 
Discussion 
 
The aim of the current study was to establish an in-depth comparison of 
ADHLSCs and HSCs, cells of human liver origin exhibiting similar 
fibroblastic morphology and both reported as stem/progenitor cells. By 
comparing these cell populations successfully isolated from the same 
donors, we i) demonstrate that ADHLSC and HSC are two distinct liver 
cell types displaying significant differences in gene expression profiles 
as well as functional features, and ii) confirm the stem/progenitor 
properties of ADHLSC. 
Using flow cytometry and immuno-cytochemistry, we confirmed the 
mesenchymal phenotype of both ADHLSCs and HSCs. Both cell 
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populations were also negative for hematopoietic and epithelial protein 
markers rendering the demonstration of their singularity difficult. 
To assess a thorough analysis of both cell types, we used microarray 
analysis and screened more than 10.000 genes on the 4 different 
samples of ADHLSC and HSC. Top 100 differentially expressed genes 
were identified. The main differences between ADHLSCs and HSCs are 
seen at the level of the chemokines expressed. Such chemotactic 
molecules which regulate the infiltration of immune cells to sites of 
inflammatory injuries, are initially all expressed in the liver. With 
respect to the first family, CCL7 seems to be the highly expressed one in 
ADHLSC in accordance with its documented role in development as 
demonstrated in neuronal differentiation [17]. CCL7 was also involved 
in the pro-inflammatory responses that may stimulate liver 
regeneration at the cellular level [18]. 
The second CXC chemokine family displays well-documented 
neutrophil chemotactic, angiogenic, and mitogenic properties [19] [20]. 
The increased expression levels of CXCL1 and CXCL6 detected in 
ADHLSC are in accordance with the parallel up-regulated level of IL-8 
and LIF. All these cytokines are directly involved in chemotaxis, cell 
movement and migration of mesenchymal stem cells [21]. 
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HGF, a pleitropic cytokine of mesenchymal origin, participates in the 
regulation of proliferation, differentiation and chemotactic migration of 
mesenchymal stem cells [22] [23]. Its high expression level in ADHLSCs 
is in accordance with their stem/progenitor features as documented in 
other MSCs. Conversely, HGF levels are abnormally decreased in 
fibrosis settings which correlate with induced proliferation of activated 
stellate cells [24]. In the same context, HGF over-expression induces a 
remarkable anti-fibrotic effect [25] [26]. The anti-fibrogenic effects of 
HGF have been attributed to the inhibition of the TGFβ pathway, the 
inhibition of other fibrogenic cytokines and to the induction of matrix 
metalloproteinases [27] as well as up-regulation of miR-29 thereby 
regulating collagen expression [28]. This result may suggest potential 
anti-fibrotic properties of ADHLSC as demonstrated for other 
mesenchymal stem cells [29] [30]. 
In our study, we did detect protein expression of cytokeratins 18 & 19 
in only HSC as demonstrated using western blotting which is in 
accordance with gene expression profiling data. The data are supported 
by the increased expression of desmoplakin, which anchors these 
intermediate filaments to desmosomes [31]. However, no data is 
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currently available regarding desmoplakin expression and its role in 
activated HSCs. 
After its interaction with dystroglycan, dystrophin forms a glycoprotein 
transmembrane complex required for spatial organization of laminin on 
the cell surface and for basement membrane assembly. Such complex is 
up regulated during spontaneous activation of HSC in culture [32]. This 
is also the case for elastin, a marker of maturity of liver fibrosis that was 
logically up regulated in HSC as compared to ADHLSC [33]. 
MMP3 (stremolysin), which degrades collagen types II, III, IV, IX, and X, 
proteoglycans, fibronectin, laminin and elastin, was the highly up-
regulated MMP in ADHLSC compared to others MMPs like MMP2 and 
MMP14. In contrast, MMP3 is down-regulated in other MSCs like 
adipose-tissue MSC, as compared to fibroblasts [34]. HSCs are known to 
express both mesenchymal and neural cell lineage markers [35]. 
Indeed, an increasing number of neural/neuroectodermal markers have 
been documented in HSCs like NCAM, nestin and NGF [36] [37] [38]. In 
our study, we confirmed this specificity of HSCs using both microarray 
and immunocytochemistry. At the protein level, we demonstrated that 
NCAM is highly expressed in HSCs as compared to ADHLSC (although 
no gene expression level difference was seen between both cell types). 
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Nestin expression presents the same profile as NCAM except that its 
protein expression is detectable in ADHLSC. Indeed, this intermediate 
filament has been described in mesenchymal stem/progenitor cells 
[39]. These data are in accordance with the described genetic profile of 
other MSCs, for which neural markers are down-regulated in 
comparison with fibroblasts [34]. Together, these phenotypic and 
genotypic characterization analyses confirmed the singularity of 
ADHLSCs and HSCs with respect to chemokines, intermediate filaments 
and neural markers expression levels.  
The functional analysis of ADHLSCs and HSCs allowed us to support the 
hypothesis that both cell populations also behave differentially in basal 
conditions. Obviously, the secretion profile of each cell type is different 
and supported the microarray data, emphasizing that ADHLSCs secrete 
cytokines of therapeutic and immuno-modulatory importance.  
In the liver, TGF-β is initially produced in non-parenchymal liver cells, 
whereas absent in fully differentiated epithelial cells [40]. TGF-β is also 
a potent activator of myofibroblast differentiation, ECM synthesis, 
migration, and oxidant production in mesenchymal cells [41]. TGF-β 
activates HSC, stimulates their ECM secretion and inhibits their 
apoptosis, which is in accordance with its pro-inflammatory effects 
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[37]. We recently demonstrated the immuno-modulatory effects of 
ADHLSC and TGF-β may participate to these effects by inhibiting 
lymphocytes proliferation, macrophages activation and 
immunoglobulins secretion [42] [43]. 
Collagen is one of the predominant structural proteins of the liver 
extracellular matrix and is involved in stem cell proliferation and 
differentiation [44] [45] [46]. Accordingly, a comparable secretion level 
was measured in both analyzed cell types. We also focused on cytokines 
implicated in the immune response and demonstrated that ADHLSC 
secreted greater amounts of pro-inflammatory cytokines like IL-7, IL-8, 
IL-9, IL-12, interferonɤ and TNFα and of some anti-inflammatory 
cytokines like IL-1ra, IL-4, IL-10 and IL-13. All these cytokines are 
secreted by adipose-derived MSC, stem cells possessing interesting 
immuno-modulatory properties [47], a feature recently also 
demonstrated in ADHLSC [42]. In addition, interferon-ɤ, even with pro-
inflammatory properties, has been described as an inhibitor of collagen 
deposition and HSC activation in vitro and in vivo [48]. 
These secretion profile analyses also suggest that ADHLSC secreted 
cytokines and growth factors may be of therapeutic and immuno-
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modulatory importance in the context of their transplantation 
development. 
VEGF has been shown to promote liver fibrosis by stimulating the 
activation, proliferation, and chemoattraction of HSCs [49] [50] [51]. In 
our study, we demonstrated that VEGF is highly secreted in ADHLSCs as 
compared to HSCs, which is in accordance with its involvement in 
wound healing [52] and regeneration process including for the liver 
[53] [54] [55]. VEGF has also been documented to be involved in 
supporting stem cell proliferation and survival [56]. 
In conclusion, our study demonstrates that ADHLSCs and HSCs 
represent two distinct hepatic cell populations. Even if they share 
numerous similar characteristics, we highlighted significant differences 
supporting their singularity mainly at the gene expression and 
secretion profile levels. This study also provides additional features 
supporting the potential therapeutic development of ADHLSC for liver 
cell-based therapy. 
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Paper 2 
Human liver mesenchymal cells inhibit human 
hepatic stellate cell activation and induce their 
secretion of anti-fibrotic molecules via HGF 
mediated paracrine effect. 
 
Berardis Silvia, Evraerts Jonathan, El Taghdouini Adil, Henriet Patrick, Smets 
Françoise, van Grunsven Leo, Najimi Mustapha, Sokal Etienne Marc.  
Submitted. 
 
HSC are considered to be the main cell type implicated in the 
extracellular matrix deposition by undergoing an activation process 
after liver injury. This activation process, characterized by an increased 
proliferation rate and an increased collagen secretion level, plays a key 
role in the development of liver fibrosis. Isolated HSC are able to 
activate in vitro after only being in contact with the plastic substrate of 
the culture dishes. Characteristics exhibited by HSC post-plating are 
similar to those described in vivo. 
In the second part of this thesis work, we investigated whether ADHLSC 
were able to inhibit the in vitro activation process of human stellate 
cells. The effects of ADHLSC on HSC were evaluated in indirect co-
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culture systems and concerned proliferation rate, produced collagen 
level and anti-fibrotic molecules secretion. 
Our data revealed that ADHLSCs were able to significantly inhibit HSC 
proliferation and their collagen production/secretion. This study shows 
the potential of ADHLSC to modulate the HSC secretome quality, in 
particular via the secretion of HGF. 
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Abstract 
 
OBJECTIVE: Progressive liver fibrosis leads to cirrhosis and end stage 
liver disease. Controlling stellate cell activation should prevent such 
evolution. In vivo studies have reported benefit of mesenchymal stem 
cell therapy to control fibrosis in rodent models, but not yet in human, 
and in vitro proof of concept using human cells remains scarce. Our aim 
was to evaluate the in vitro effect of a specific sub population of 
mesenchymal stem cells harvested from the human liver, the Adult 
Derived Human Liver Mesenchymal stem/progenitor cells (ADHLSCs) 
on the activation and secretome profile of autologous and allogeneic 
human Hepatic Stellate Cells (HSCs).  
DESIGN: Indirect co-culture systems used different concentration ratios 
of ADHLSCs and HSCs, or the conditioned ADHLSC culture media. . HSC 
number and viability were evaluated by microscopy and biochemical 
assays whereas proliferation was analyzed using flow cytometry and 
immunocytochemistry. The HSC secretion profile was evaluated by 
Elisa and Luminex. 
RESULTS: HSC proliferation was inhibited from 24 hours to 7 days 
when co-cultured with ADHLSCs or their conditioned medium. Plating 
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was delayed, and HSCs were blocked in G0/G1 phase, with decreased 
Ki-67 positivity. Pro-collagen I production was reduced and an 
increased secretion of HGF, IL-6, MMP1 & MMP2 by HSCs was 
measured. Neutralization of HGF partially blocked the inhibitory effect 
of ADHLSCs on HSC proliferation and secretion profile.  
CONCLUSION: These data provide mechanisms for the anti-fibrotic 
potential of ADHLSCs, opening the prospect of clinical trials in liver 
fibrosis.  
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Introduction 
 
Liver fibrosis control remains an unmet medical need. It occurs in 
response to chronic liver injury and leads to cirrhosis and end stage 
liver disease (1;2). Patients require liver transplantation and face long 
waiting time with progressive disabilities (3). Progressive fibrosis of 
the graft may also occur after successful transplant (4). Despite the 
improved understanding of mechanisms underlying liver fibrosis 
development, the efficacy of most drugs has not been proven in humans 
(1;5).  
Hepatic stellate cells (HSCs) are the main extracellular matrix-
producing cells. Following liver injury, HSCs undergo an activation 
process characterized by the adoption of proliferative, contractile and 
fibrogenic myofibroblast features (6), a process that can be reproduced 
in culture plastic dishes (7). Ideal anti-fibrotic therapy should modulate 
HSC activation, inhibit collagen synthesis and enhance matrix 
degradation (8). 
Mesenchymal stem cells (MSCs) are proposed to treat fibrosis, on the 
basis of their hepatocyte differentiation and regeneration potential as 
well as their immunomodulatory properties (9-11). The Adult Derived 
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Human Liver Stem Cell is a subtype of MSC obtained following 
collagenase digestion of the liver, with a preferential hepatocyte 
differentiation pattern (12) (13). MSCs, including ADHLSCs, can 
produce growth factors and cytokines able to suppress the 
inflammatory responses (14;15). Moreover, MSCs have the potential to 
exert a suppressive effect on immune cells (16). 
Extra-hepatic MSCs were reported to reverse fibrosis in animal models 
of induced liver fibrosis (17;18), with a frequent improvement of the 
hepatic function. The underlying mechanisms are not yet understood. In 
vitro models are therefore required to better understand how HSC 
activation can be modulated by MSCs, and their paracrine properties 
(19-21). Ideally, these systems should use human derived cells as 
rodent cells may behave and react differently. 
ADHLSCs engraft and differentiate in hepatocyte like cells in rodents, 
and have been infused safely and successfully in children with inborn 
errors of liver metabolism (10) (11) (22) (23). 
In the current study, we investigated the ability of ADHLSCs to 
modulate the activation of autologous and allogeneic human stellate 
cells (HSCs) in vitro in an indirect co-culture system.  
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Materials and methods 
 
ADHLSC and HSC isolation and culture 
The protocol  and  experiments  were  approved  by  the  ethical  
committees  of  St-Luc Hospital and Medicine faculty of Université 
Catholique de Louvain. An agreement from the Belgian Ministry of 
Health was obtained for Hepatocytes and Hepatic Stem Cells isolation 
and banking. A written and signed informed consent has been obtained 
for each human liver used in the current study (n=4, Table 1).  
 
 
 
Table 1: Characteristics of the four liver donors used for the isolation of both HSC and 
ADHLSC studied in the current work. 
 
Donor 
number 
Age Gend
er 
Reason of death or 
liver 
transplantation 
Blood 
group 
Ischemia 
time 
89 3 days M Respiratory A+ 4 hours 
93 2 
years 
F Metabolic disease 
(Liver transplanted) 
O+ 1 hour 43 
98 7 days M Cardio-respiratory 
arrest 
 
O- 4 hours 20 
105 46 
years 
F Trauma 
 
B+  9 hours 43  
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Each liver was isolated using a two-step collagenase perfusion. The 
obtained crude liver cell suspension was submitted to filtration and low 
speed centrifugation. The recovered pellet containing liver cells of the 
parenchymal fraction (mainly hepatocytes) was submitted to primary 
culture. ADHLSCs were subsequently obtained as previously described 
(12;15). The supernatant containing the corresponding non-
parenchymal fraction was submitted to a Nycodenz gradient 
(Myegaard, Oslo, Norway) centrifugation step in order to isolate HSCs 
(24). 
Both  liver cell  types  were  cultured  using  DMEM  containing  4.5g/L  
glucose  (Life Technologies) supplemented  with  10%  Fetal  Calf  
Serum (FCS)  (Life Technologies)  and  1%  Penicillin/Streptomycin 
(Life Technologies),  at  37°C  in  a  fully  humidified  atmosphere  (5%  
CO2) as previously described (15). When reaching  80% confluence,  
cells  were  lifted  with  0.05%  Trypsin-EDTA  (Life Technologies)  and  
replated  at  a density of 5000 cells/cm². The viability of recovered cells 
was evaluated using trypan blue exclusion assay at each passage. 
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Co-culture systems 
In order to evaluate the interactions between ADHLSCs and activated 
HSCs, indirect co-culture Transwells were used. HSCs were seeded in 
the lower chamber of a 6-well plate at a density of 10.000 cells/cm² 
while ADHLSCs were placed on collagen-coated membrane inserts (24 
mm diameter, 0.4 µm pore size; Corning), with ADHLSC/HSC ratios of 
1/100, 1/10, 1/1 and 0/1. The impact of ADHLSCs on HSCs was 
evaluated by collecting HSCs at 1, 4 and 7 days for analysis. Cell number 
and viability were evaluated using microscopy and Trypan blue 
exclusion assays. 
 
Biochemical evaluation of HSC number 
Sensitive colorimetric assay Cell Counting Kit-8 (CCK-8) (Sigma) allows 
the determination of the number of viable cells, following the reduction 
of the tetrazolium salt WST-8 by the cell dehydrogenases, giving rise to 
a yellow colored product (Formazan). The amount of Formazan 
produced is directly proportional to the number of viable cells. 
After co-culture, HSC were lifted with 0.05% Trypsin-EDTA (Life 
Technologies). For each condition, 100 µl of the cell suspension were 
added into each well of 96-well plates and incubated for 15 minutes at 
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37°C in a fully humidified atmosphere (5% CO2). A calibration curve 
using determined viable cells amounts was performed for each 
experiment. Ten µl of the CCK-8 solution were added per well and the 
plates were incubated for 2 hours at 37°C in a fully humidified 
atmosphere. Absorbance was thereafter measured at 450 nm using a 
Victor X4 plate Reader (Perkin Elmer). 
 
Flow cytometry 
For cell cycle analysis, HSCs were lifted with 0.05% Trypsin-EDTA (Life 
Technologies) after co-culture. Two hundred thousand cells were used 
for each condition. Cell suspensions were centrifuged, washed twice 
with PBS, fixed with 700µl of cold ethanol and incubated for 30 minutes 
on ice. HSC were then washed again with PBS before being incubated 
with 100 µg/ml Propidium Iodide (Life Technologies), 0.1 mg/ml RNase 
(Sigma) and 0.1% Triton X-100 (Sigma) for 30 minutes at 37°C and then 
for 15 minutes on ice, before reading with a  CANTO  II  flow  cytometer. 
The analyses were performed using the BD FACSDiva Software. The 
different phases of the cell cycle were determined by measuring the 
area under the curve using the FlowJo Software. 
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Immunocytochemistry 
After 24 hours incubation with ADHLSC or HSC conditioned medium in 
24 well plates, cells to analyze were fixed using paraformaldehyde 
3.5%, for 15 min at room temperature. Endogenous peroxidase was 
eliminated using hydrogen peroxide 3.3% for 3 minutes. All steps were 
performed at room temperature. Cells were permeabilized using PBS 
containing 1% Triton X-100 (Sigma) for 10 minutes. Non-specific 
immuno-staining was prevented by 1h incubation in PBS containing 1% 
Bovine Serum Albumin (Sigma). Thereafter, cells were incubated with 
Ki-67 antibody (Dako) at a concentration of 1/150 for 1h.  After 
washing, cells were incubated with secondary antibody (EnVision – 
Dako) during 30 minutes. Revelation was performed after 5 minutes 
incubation with liquid DAB and chromogen substrate (Dako). 
Counterstaining was performed using Mayer’s hematoxylin for 10 
minutes. Preparations were then mounted for microscopic analysis 
(DMIL, Leica, Belgium). For each experimental condition, four different 
fields were analyzed and the stained / unstained nuclei were counted 
using the ImageJ Software for a total of 2500 nuclei. 
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Apoptosis assay 
Apoptosis of HSC was determined using FITC Annexin V Apoptosis 
Detection Kit I (BD Pharmingen). The experiments were performed 
according to the manufacturer’s instructions. Briefly, HSCs were 
harvested, washed with PBS and resuspended in 100µl of Annexin V 
binding buffer before adding 5µl of Annexin V and 5µl of Propidium 
iodide. After an incubation of 15 minutes in the dark and the addition of 
400µl of Annexin V binding buffer, cells were analyzed by flow 
cytometer (Canto II, BD). Cells treated with 1mM Hydrogen Peroxide 
were used as positive control for apoptosis. 
 
ELISA 
After removal of the inserts containing ADHLSC and medium aspiration, 
recovered HSC were washed with sterile PBS and a serum-free medium 
(DMEM  containing  4.5g/L  glucose  (Life Technologies)) was added for 
24 hours.  Thereafter, supernatants were collected and cells were lifted 
for counting and evaluation of viability. Collagen  secretion  was 
evaluated using an Elisa  kit  for  the  procollagen  type  I  C-Peptide  
(Takara  Bio  Inc,  Japan). The experiments were performed according 
to the manufacturer’s instructions. The measurement of the absorbance 
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at 450 nm was done with a Victor X4 plate Reader (PerkinElmer). The 
results were randomized according to the number of cells collected. 
 
Luminex analysis 
The secretome of HSCs after 24 hours of co-culture was evaluated using 
a 9-plex kit (TNFα, MMP-9, MMP-2, Interferon ɤ, HGF, IL-6, MMP-1, IL-
10 and MMP-13) (R&D Systems) and the Luminex technology (Bio-Plex 
200, Biorad). The supernatants were prepared as previously described 
for the pro-collagen type I C-Peptide Elisa. The principle of the 
technique is based on color-coded beads, which enable the detection of 
up to 100 cytokines simultaneously. The primary antibody directed 
against the target protein is conjugated with the dyed beads. After 
several washes to remove unbounded proteins, a secondary 
biotinylated antibody is added to the reaction. Streptavidin-
phycoerythrin (Streptavidin-PE) is then added to bind the biotinylated 
antibody. By measuring the relative fluorescence intensity, the antigen-
antibody reaction can be evaluated. The assays were performed 
following the manufacturer’s instructions. 
Briefly, after the pre-wetting of the plate, 50µl of the beads were added 
into each well. Fifty µl of the samples were then added into each well 
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and the plate was incubated for 2 hours at room temperature on a plate 
shaker at 200 rpm. The plate was then washed three times with the 
Wash Buffer and 50 µl of the diluted Biotin antibody was added to each 
well. After an incubation of 1 hour at room temperature with shaking, 
the plate was washed three times before adding 50 µl of the 
Streptavidin-PE solution into each well. Finally, after an incubation of 
30 minutes on a plate shaker at 200 rpm and three washes, the beads 
were resuspended with 100µl of Wash Buffer into each well. After an 
incubation of 2 minutes at room temperature on a plate shaker at 200 
rpm, the plate was read by the Luminex machine, and the data were 
analyzed using Bio-Plex Manager 6.0. 
 
HGF neutralization 
Neutralization of HGF was performed using 20µg/ml anti-HGF antibody 
(R&D Systems), diluted in the conditioned medium. The conditioned 
medium without anti-HGF served as control. The antibody was 
incubated in the ADHLSC/HSC corresponding conditioned medium for 
1 hour at 37°C before being in contact with HSCs.  After a 24 hour 
incubation, HSCs were lifted for counting, viability assay and secretome 
analysis. 
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Statistics 
Results are expressed as mean ± standard error of the mean (SEM). 
Statistical differences were determined by paired Student's t-test for 
two samples analysis and One way ANOVA followed by the Newman-
Keuls post-hoc test. Differences were considered significant when p 
values *p<0.05, **p<0.01, ***p<0.001. 
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Results 
 
The decrease of HSC recovery induced by ADHLSCs is associated to 
an inhibition of both plating and proliferation 
 
We investigated the influence of ADHLSCs on the modulation of the 
activation process of HSCs. We mainly studied the indirect interactions 
between both cell types, by using a Transwell co-culture system. For 
each experiment, both ADHLSCs and HSCs used were obtained from the 
same human donor liver.  
As activated HSCs are characterized by an increased proliferation rate, 
we first analyzed the influence of ADHLSCs on their recovered number. 
After plating an initial HSC cell number in the lower chamber, ADHLSCs 
were placed on the collagen-coated membrane insert with 
ADHLSC/HSC ratios of 0/1, 1/100, 1/10 and 1/1. Activated HSCs from 4 
different donors were collected after 24 hours, 4 days and 7 days of co-
culture with ADHLSCs. A significant decrease in the number of 
recovered HSCs was noted after 24 hours of co-culture. To avoid 
operator bias, recovered HSC number was independently evaluated and 
the diminution was confirmed by three different investigators. In 
163 
 
addition, the decrease in the number of recovered HSCs was optimal 
when the lowest ADHLSC density (1/100 ratio) was used in the co-
culture (42 ± 5 % vs 36 ± 6 % vs 81 ± 7 %  for 1/100, 1/10 and 1/1 
culture conditions respectively) (Figure 1A & 1B). Our data also 
revealed that the inhibitory effect initiated in the first 24 hours, was 
maintained after 4 and 7 days of co-culture for all culture conditions 
(Figure 1 B).  
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Figure 1: Effect of ADHLSC on HSC culture. A, Morphology of HSC recovered after 24 
hours of co-culture with no ADHLSC (A1) or with a ADHLSC/HSC ratio of 1/100 (A2). 
B, The analysis of the number of adhering HSC collected after co-culture with ADHLSC 
revealed a significant decrease in HSC number after 24 hours at an ADHLSC/HSC ratio 
of 1/100. This effect was maintained up to 7 days (n=6 for 24 hours; n=4 for 4 days 
and 7 days). C, The analysis of HSC number after 24hours of co-culture with ADHLSC 
using CCK8 biochemical assay revealed a significant decrease in HSC number at an 
ADHLSC/HSC ratio of 1/100 (n=4). Results are expressed as mean ± standard error of 
the mean (SEM). *** denotes a p value <0,001; ** p<0,01;  * p<0,05. 
 
Several quality control experiments were performed in order to 
validate the model. Firstly, ADHLSCs were seeded alone in an insert for 
24 hours. Thereafter, the ADHLSC containing insert was added to HSCs 
that were seeded in a lower chamber. After 24 hours co-culture, we did 
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observe the same decrease in HSC number as with ADHLSC/HSC ratio 
of 1/100 (data not shown). Secondly, we investigated if this ADHLSC 
inhibitory effect on HSCs could be potentiated by replacing the insert 
with one containing freshly trypsinized cells. After 24 hours of co-
culture, the addition of the new insert did not induce additional 
decrease of HSC number as compared to the conditions mentioned 
above (data not shown).  
To strengthen the result we observed after microscopically counting 
HSCs post-co-culture with ADHLSCs, we analyzed HSC recovered 
number using the CCK-8 biochemical assay. After 24h, we demonstrated 
that HSCs co-cultured with 1/100 ADHLSC density showed a 30% 
decrease of cell number (100 ± 19.7 % vs 71.3 ± 13.0 % for 0/1 and 
1/100 culture conditions respectively) (Figure 1C).  
 
Thereafter, we went into further analysis of the mechanisms behind the 
diminished number of adhering HSCs obtained after 24h co-culture 
with ADHLSC. To do so, we investigated whether this could be related 
to deficient plating, inhibition of proliferation and/or induced cell 
death. We firstly followed the plating of HSC 24h after the initiation of 
the co-culture. We counted HSCs in the floating fraction and compared 
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their number to those obtained after enzymatic detachment. When 
focusing on the counted adhering fraction, we confirmed the decreased 
HSC number in the 1/100 co-culture conditions (100 ± 9.3% vs 61 ± 
6.5% for 0/1 and 1/100 culture conditions respectively). When 
analyzing the number of HSCs present in the floating fraction, we 
revealed that it was significantly 4 times higher in the condition for 
which HSCs were co-cultured with ADHLSCs at 1/100 ratio (Figure 2A). 
When considering 100% as the sum of the recovered HSCs in both 
floating and adhering fractions, we demonstrated that HSC number in 
the floating fraction is increased up to 13.7 ± 0.8 % in the 1/100 co-
culture condition as compared to 2 ± 0.4% in the 0/1 group (Figure 2A). 
In the adhering fraction, we revealed that the 1/100 co-culture 
condition logically represents 86.4 ± 0.8 % as compared to 97.8 ± 0.4 % 
in the 0/1 co-culture group (Figure 2A).     
Thereafter, we checked whether the same effect may be obtained by 
using ADHLSC conditioned culture medium. Both ADHLSCs and HSCs 
(as controls) were seeded separately at the same initial density than in 
the co-culture conditions. Then, the culture supernatants were collected 
after 24 hours and freshly trypsinized HSCs were incubated with these 
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recovered conditioned media for 24 hours. HSCs were then lifted for 
counting and viability evaluation. 
The same effect was observed when HSCs were only incubated with 
conditioned culture medium of ADHLSCs. Indeed, we demonstrated a 
similar decrease in the number of adhering HSCs (100 ± 19.1 % vs 62.1 
± 16.4 % for 0/1 and 1/100 culture conditions respectively) 
concomitantly to an increase in the number of floating HSCs (100 % vs 
280 % for 0/1 and 1/100 culture conditions respectively). When 
considering 100% as the sum of the recovered HSC in both floating and 
adhering fractions, we observed that HSC number in the floating 
fraction is increased up to 12 ± 2.1 % in the 1/100 co-culture condition 
as compared to 3 ± 1.4% in the 0/1 group (Figure 2B). In the adhering 
fraction, we revealed that the 1/100 co-culture condition logically 
represents 88 ± 2.1 % as compared to 97 ± 1.4 % in the 0/1 co-culture 
group (Figure 2B).     
The same described effect was obtained when using allogeneic 
ADHLSCs (data not shown).  
We also evaluated the HSC death using flow cytometry and Annexin V - 
PI staining. We did not observe any difference in cell death induction 
between HSCs incubated with ADHLSC conditioned medium and those 
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cultivated with HSC conditioned medium (Figure 2C). The majority of 
the cells were viable cells as they were negative for both Annexin V and 
PI staining. Only a small amount of cells were in early (Annexin V+ / PI-) 
or late (Annexin V+ / PI+) apoptosis (Figure 2C). 
 
 
 
Figure 2: Effect of ADHLSC on HSC plating and viability. A, The counting of floating 
and adhering HSC number after 24 hours of co-culture with ADHLSC showed an 
increase in the number of floating HSC concomitant with a decrease in the number of 
adhering HSC at an ADHLSC/HSC ratio of 1/100 (n=4). B, The counting of the number 
of floating and adhering HSC after 24 hours of incubation with ADHLSC conditioned 
medium showed similarly an increase in the % of floating HSC and a decrease in the % 
of adhering HSC, as compared with HSC incubated the same period of time with HSC 
conditioned medium (n=4). C, Following Annexin V – PI staining, no significant 
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difference in cell death induction was noticed between HSC cultivated for 24 hours 
with ADHLSC or with HSC conditioned medium (n=4). Results are expressed as mean 
± standard error of the mean (SEM). *** denotes a p value <0,001; **p<0,01;  * p<0,05. 
 
 
In order to understand the kinetic of this deficient plating, we analyzed 
HSC number both in the floating and adhering fractions at different time 
points post-seeding with either ADHLSC or HSC conditioned medium. 
Our results demonstrated that the number of HSCs incubated with 
ADHLSC conditioned medium and then not adhering yet is 2 times 
higher in the floating fraction as compared to control HSCs, early after 
seeding (34 ± 5% vs 16 ± 2.9% at 2 hours; 21 ± 5% vs 12 ± 2.9 % at 4 
hours) (Figure 3A). This delayed plating remained maintained and 
optimal after 24h post-seeding (16 ± 2.9% vs 5 ± 1.1 % at 8 hours; 10 ± 
2.1%  vs 3 ± 1.2% at 24 hours) (Figure 3A). In parallel, the number of 
adhering cells was also evaluated and confirmed a low HSC number 
when incubated with ADHLSC conditioned medium as compared to 
control group (66 ± 4.9% vs 84 ± 2.9% at 2 hours; 79 ± 5 % vs 88 ± 
2.9% at 4 hours; 84 ± 2.9% vs 95 ± 1.1% at 8 hours; 70 ± 1.2 % vs 91 ± 
2.1 % at 24 hours) (Figure 3B). 
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Figure 3: ADHLSC delay HSC post-seeding adhesion. The plating kinetic analysis 
revealed a higher number of floating HSC (A) and a lower number of adhering HSC (B) 
at 2, 4, 8 and 24 hours post-seeding in the group of HSC incubated with ADHLSC 
conditioned medium in comparison with the group incubated with HSC conditioned 
medium (n=4). Results are expressed as mean ± standard error of the mean (SEM).  
*** denotes a p value <0,001; **p<0,01;  *p<0,05. 
 
 
 
The evaluation of HSC cycle was carried out with PI staining and flow 
cytometry whereas the data were analyzed using Flow Jo software. For 
these results, we demonstrated that 59 ± 4.2% of HSCs co-cultured for 
24 hours with ADHLSCs at ratio 1/100 are blocked in G0/G1 phase as 
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compared to control cells (44 ± 6.5%) (Figure 4A). While no significant 
difference was seen for S phase, we revealed a significant decrease in 
the number of HSC in the G2/M phase when co-cultured with ADHLSC 
(5 ± 2.4%) as compared to control HSC (15 ± 1.7%) (Figure 4A). The 
same result was obtained when HSCs were incubated with conditioned 
medium of ADHLSCs both with respect to G0/G1 phase (70 ± 8.9 % for 
HSC incubated with ADHLSC conditioned medium vs 50 ± 14.5% for 
HSC incubated with HSC medium) as well as G2/M phase (3 ± 2% when 
incubated with ADHLSC medium as compared to 11 ± 3.1% when HSCs 
were incubated with HSC conditioned medium) (Figure 4B). Moreover, 
we observed the same proliferation inhibition (increase in the number 
of cells in G0/G1 phase and decrease in the number of cells in G2/M 
phase) when HSC were seeded during 24 hours before being in contact 
with ADHLSC conditioned medium (data not shown). In parallel, we 
used immunocytochemistry for Ki67 protein to confirm flow cytometry 
data. The number of immunostained nuclei was evaluated on 4 different 
microscopy fields per donor using the Image J software for a total of 
2500 nuclei (Figure 4C). We observed a significant decrease in the 
number of immunopositive HSC nuclei after an incubation of 24 hours 
with ADHLSC conditioned medium (23 ± 1.7%) in comparison with 
172 
 
HSCs incubated with HSC medium (46 ± 2.9%) which corroborates with 
a decrease in the number of proliferating cells. 
 
 
 
Figure 4: Effect of ADHLSC on HSC proliferation. HSC cycle analysis using PI 
staining demonstrated an increase in the number of HSC blocked in the G0/G1 phase 
and a decrease of the number of HSC in the G2/M phase after 24 hours of co-culture 
with ADHLSC at an ADHLSC/HSC ratio of 1/100 (A) and after 24 hours of incubation 
with ADHLSC conditioned medium (B) (n=4). C, The Ki67 immunostaining of HSC 
showed a significant decrease of the number of immunostained nuclei of HSC pre-
incubated for 24 hours with ADHLSC conditioned medium, in comparison with the 
HSC group incubated with HSC conditioned medium (n=4). For each experimental 
condition, four different fields were analyzed and a total of 2500 nuclei were counted 
using Image J software. Results are expressed as mean ± standard error of the mean 
(SEM). *** denotes a p value <0,001; **p<0,01;  *p<0,05. 
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ADHLSCs modulate HSC secretion profile by inhibiting pro-
collagen type I and stimulating the extracellular release of anti-
fibrotic molecules  
 
Upon activation, HSCs are known to increase their secretion of collagen 
type I, one of the major components of the extracellular matrix. 
Therefore, we investigated the influence of ADHLSCs on the collagen 
secretion capacity of HSCs by measuring the pro-collagen I (precursor 
of the collagen type I) secretion using Elisa assay. HSCs were incubated 
with ADHLSCs at a ratio of 1/100 for 24 hours. Then, culture medium 
was discarded and fresh serum free medium was added for an 
additional 24 hours. The supernatants were collected and adhering 
HSCs were lifted for counting and viability evaluation. We 
demonstrated a significant 45% decrease in the amount of pro-collagen 
I secreted by HSCs when co-cultured with ADHLSCs (210.2 ± 56.8 
ng/ml/24h/105 cells) in comparison with the control group (384.4 ±  
77.2 ng/ml/24h/105 cells) (Figure 5A). 
Using a multiplex Luminex assay, we also demonstrated that the levels 
of secreted HGF by HSCs was increased when co-cultured with 
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ADHLSCs at a ratio of 1/100 (31.6 ± 6.6 pg/ml/24h/105 cells) as 
compared to control HSCs (16.1 ± 4.8 pg/ml/24h/105 cells). The same 
tendency is observed for IL-6 (29.8 ± 15.4 pg/ml/24h/105 cells for 
control vs 66.1 ± 31.7 pg/ml/24h/105 cells for HSCs co-cultured with 
ADHLSCs) (Figure 5B). 
 
 
Figure 5: HSC secretome modulation after 24 hours of co-culture with ADHLSC. 
A, ADHLSC inhibit pro-collagen type I secretion by HSC after 24 hours co-culture with 
ADHLSC at a ADHLSC/ HSC ratio of 1/100, as evaluated by ELISA (n=4). B, ADHLSC 
increase HGF and IL-6 secretion by HSC after 24 hours co-culture with ADHLSC at a 
ADHLSC/ HSC ratio of 1/100, as evaluated by multiplex technology (Luminex) (n=4). 
Results are expressed as mean ± standard error of the mean (SEM). *** denotes a p 
value <0,001; **p<0,01 ; *p<0,05. 
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The secreted levels of metalloproteinases MMP1 and MMP2, involved in 
the extracellular matrix degradation, were also increased after 24 hours 
of co-culture with ADHLSCs (Table 2). This tendency was observed for 
each donor, even if high inter-donor variability was noticed.  
 
 
 
Table 2: HSC MMP secretion level 
 
 
  MMP1 (pg/ml/24h/100 000 cells) MMP2 (pg/ml/24h/100 000 cells) 
  Donor 1 Donor 2 Donor 3 Donor 4 Donor 1 Donor 2 Donor 3 Donor 4 
ADHLSC/HSC 
ratio     
0/1 474,18 1183,05 1005,03 4550,99 329,02 469,68 1919,75 1959,93 
1/100 843,57 1515,79 2248,78 6462,41 466,6 718,12 3288,16 2496,38 
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Neutralization of HGF reversed the inhibitory effect of ADHLSCs on 
both HSC number and secretion profile 
 
As previously described, ADHLSCs secrete high levels of HGF, a growth 
factor known to exhibit anti-fibrotic properties (15). As the inhibitory 
effect of ADHLSCs on HSC proliferation seems to be mediated by soluble 
factors, we investigated the potential role of HGF by neutralizing this 
growth factor. HSCs were incubated with the conditioned medium 
(from ADHLSC or HSC) supplemented with anti-HGF antibody (20 
µg/ml). After 24 hours, we proceeded to HSC counting and viability 
evaluation. With respect to the floating fraction, we did not see any 
effect of HGF on the floating HSC population (100 ± 24% for control 
HSCs; 108 ± 11% for HSCs pre-incubated with anti-HGF antibody; 277 ± 
23% for HSC incubated with ADHLSC conditioned medium; 254 ± 22% 
for HSC incubated with both ADHLSC conditioned medium and anti-
HGF) (Figure 6A). Nevertheless, HGF seems more involved in 
modulating the HSC adhering fraction. Indeed, when anti-HGF was 
diluted in ADHLSC conditioned medium, it partially inhibited the 
decrease of HSC number (86 ± 3%) normally detected when HSCs were 
incubated with ADHLSC conditioned medium alone (64 ± 3%) (Figure 
177 
 
6A). No effect of HGF antibody was noted when incubated with HSC 
conditioned medium. 
We also studied the effect of HGF neutralization on the HSC secretion 
profile. After a wash-out of 24 hours with serum free medium, we 
evaluated the HSC pro-collagen I secretion using ELISA. We 
demonstrated that anti-HGF blocked the inhibitory effect on collagen 
secretion by HSCs when incubated during the 24 hours co-culture with 
ADHLSC conditioned medium (Figure 6B). Neutralization of HGF during 
the ADHLSC/HSC co-culture step also significantly inhibited the HSC 
secretion of IL-6, HGF, MMP1 and MMP2 (Figure 6C). 
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Figure 6: Involvement of HGF in the effect of ADHLSC on HSC proliferation and 
pro-collagen type I secretion. A, The counting of floating and adhering HSC number 
after 24 hours of incubation with ADHLSC or HSC conditioned medium was evaluated 
after pre-incubation with or without anti-HGF antibody. Results showed a significant 
partial inhibition of the decrease in the number of adhering HSC when incubated with 
ADHLSC conditioned medium containing anti-HGF (n > 5). B, Inhibition of the effect of 
ADHLSC conditioned medium on HSC pro-collagen type I secretion when anti-HGF 
antibody was added (n=3). C, Anti-HGF antibody significantly inhibited the increase of 
HGF, IL-6, MMP1 & 2 secretion by HSC when supplemented during their 24 hours co-
culture with ADHLSC conditioned medium. The analysis was performed via multiplex 
technology (Luminex) (n=4). Results are expressed as mean ± standard error of the 
mean (SEM). *** denotes a p value <0,001; **p<0,01;  *p<0,05. 
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Discussion 
 
The novelty of our work is to bring evidence and mechanisms by which 
human liver derived mesenchymal cells, or their secretome, could be 
used as anti-fibrotic agents.  Existing in vivo studies suggest the 
potential benefit of mesenchymal stem cells (MSCs) infusion to reverse 
fibrosis in diseased animal livers (25) (26) (27), and to improve liver 
function  in human liver diseases (28) (29). One study in human has 
reported histological improvements following intra-arterial infusion of 
human BM-MSCs in alcoholic patients (30). In vitro, the indirect 
interaction between human bone marrow derived MSCs (BM-MSCs) 
and human liver derived stellate cells was investigated; the authors 
showed that BM-MSCs in transwell co-culture systems inhibit stellate 
cell proliferation and induce their apoptosis, via nerve growth factor 
secretion (31).  No information was obtained on collagen production by 
HSCs, nor on MMP and other soluble factor secretion by MSCs or HSCs.  
In a separate in vitro study using rodent stellate cells, human MSCs 
reduced HSC proliferation and pro-collagen I production (19). 
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Our study brings additional clues to the interaction mechanisms 
involved in man.  We selected human liver derived MSCs (ADHLSCs), as 
these resident cells are more closely related to the liver (12). They 
display immuno-modulatory properties (32), have a more pronounced 
differentiation capacity into hepatocyte like cells and participate to liver 
regeneration (33) (12) (13): these latter characteristics are said to be 
associated to anti-fibrotic effects (9) (25) (27). 
We demonstrated that bioactive factors, constitutively secreted by 
ADHLSCs can modulate the activated phenotype of autologous and 
allogeneic human HSCs, inhibit their proliferation and reduce their pro-
collagen type I secretion in vitro. Secretion of MMPs were attributed to 
MSCs in previous in vivo studies (34-36). Our human cell based in vitro 
model allows to identify HSCs themselves as a source of MMP and other 
anti-fibrotic molecules. ADHLSCs appear indeed not only to secrete 
these soluble factors (like HGF) (15), but also to stimulate the secretion 
of various potential anti-fibrotic molecules by HSCs, i.e. MMP1& 2, HGF 
and IL6. This suggests the possible co-implication of an autocrine loop 
of HSCs in the anti-fibrotic process induced by ADHLSCs. 
When HSCs are plated in culture plastic dishes, they progressively lose 
their vitamin A stores, proliferate and increase their extracellular 
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matrix production, mimicking the in vivo transformation into 
myofibroblasts.(7). 
The inhibitory effect on HSC’s proliferation and collagen production 
was observed when the number of ADHLSCs used was one hundred 
times lower than the number of plated HSCs. This effect could be 
reproduced using ADHLSC conditioned medium, both with autologous 
and allogeneic cells.  
The finding that inhibition of HSC proliferation was inversely 
proportional to the number of ADHLSCs used is a striking difference 
compared to observations with extra hepatic MSCs (19) (20); this may 
be explained either by the secretion of an inhibitory molecule by 
ADHLSCs or HSCs themselves when submitted to higher ADHLSC/HSC 
ratios, or by a more efficient action of the soluble antifibrotic factor(s) 
at a determined concentration. 
To assess further the mechanism by which HSC proliferation could be 
inhibited, we blocked the secretion of HGF, one of the factors found to 
be highly secreted by ADHLSCs (15). HGF neutralization partially 
reversed the inhibitory effect of ADHLSCs on HSC proliferation. These 
data are in accordance with published data, describing the ability of 
183 
 
HGF to inhibit the platelet derived growth factor (PDGF) mediated over-
proliferation of myofibroblasts (37).  
The decrease in the amount of pro-collagen type 1 secreted by HSCs is 
promising as the collagen type 1 represents the major component of the 
extracellular matrix produced in excess during the development of liver 
fibrosis. HGF neutralization also reverted the ADHLSC-induced 
inhibition of HSC pro-collagen I secretion, in accordance with previous 
data showing the ability of HGF to inhibit the pro-fibrogenic TGF-β 
pathway (37). HGF can induce the production of metalloproteinases by 
lung myofibroblasts (37), and we showed  that HSCs also increased 
their secretion of MMP1 and 2, both involved in extracellular matrix 
degradation. The increase of the secretion level of IL-6 by HSCs in our 
model can also be of therapeutic importance as this cytokine is 
implicated in the regeneration and survival of hepatocytes (38). A 
recent study demonstrated that IL-6 and murine MSCs synergistically 
enhanced hepatic repair, improved hepatic function and reduced liver 
fibrosis in mice (39).  
Only a small number of ADHLSCs seem necessary to exert the beneficial 
inhibitory effect on activated HSCs. The use of allogeneic cells is 
conceivable as the modulation of HSC activation was efficiently 
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reproduced with allogeneic ADHLSCs. These findings seem potentially 
attractive for the development of a cell-based therapy dedicated to liver 
fibrosis. The maximal effect was observed for a ratio of 1 ADHLSC /1OO 
HSCs. According to the number of stellate cells in the human liver, the 
quantity of ADHLSCs required to treat a patient would be 240 million 
cells, a quantity that can easily be infused in a patient (10) (11;40). 
 
In conclusion, we show the capacity of human liver derived MSCs 
(ADHLSCs) to modulate the activation of human HSCs in vitro, via a 
paracrine mechanism. Inhibition of HSC proliferation and pro-collagen 
secretion as well as up-regulated secretion of anti-fibrotic molecules by 
HSCs, seem to be the likely involved mechanisms. These effects seem to 
be mediated at least in part by HGF highly secreted by ADHLSCs. 
ADHLSCs and/or their secretome are therefore candidates for liver 
fibrosis treatment.  
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Evaluation of the anti-fibrotic properties of 
ADHLSC in an animal model of induced liver 
fibrosis: preliminary results 
 
The in vitro results generated in the current thesis allow us to consider 
the potential use of ADHLSCs for the treatment of liver fibrosis. 
In vivo studies are currently ongoing and may provide additional and 
exploitable information regarding the benefit of ADHLSCs in a fibrotic 
liver environment. 
 
In order to address this issue, we transplanted undifferentiated 
ADHLSCs in SCID Beige mice in which liver fibrosis was induced by 
chronic intraperitoneal injections of CCl4, a widely used toxic. The 
mentioned animal model is well standardized and characterized 
according to the literature. A centrolobular necrosis followed by a 
wound healing response is generated after the transformation of CCl4 
into a toxic radical CCL3- by CYP2E1. Significant fibrosis develops 2-4 
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weeks after CCl4 administration. Severe bridging fibrosis occurs after 5-
7 weeks, cirrhosis after 8 to 9 weeks whereas portal hypertension and 
ascites progressively appear after 10-20 weeks [1] [2].    
The immunosuppressed SCID Beige mice were used is the current 
experiments because they i) lack NK cells, B and T lymphocytes; NK 
cells displaying anti-fibrotic properties [3], ii) develop an hepatic 
fibrosis comparable to wild-type mice [4]. 
 
Seven-week-old-mice were injected twice a week with CCl4 (0.5 ml/kg) 
during 3 weeks, in order to induce the development of liver fibrosis. 
Fourty-eight hours after the sixth injection of CCl4, one million of 
suspended ADHLSCs was intrasplenically injected (n=12)and CCl4 
injections were carried on for two additional weeks. Control sham mice 
received an intrasplenic injection of the vehicle (PBS/NAC) (n=5). Mice 
were sacrificed 48 hours after the last injection of CCl4 after which 
blood and liver samples were recovered. The fibrosis level was 
evaluated on liver slices using Sirius Red staining whereas the activated 
murine hepatic stellate cells were identified with ASMA 
immunostaining. The gene expression of murine fibrosis markers 
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(ASMA and collagen I) was evaluated using RT-qPCR. Finally, the level 
of ALT was measured in the serum of the sacrificed mice, in order to 
evaluate their liver function. The experimental protocol is represented 
in figure 1. 
 
 
 
Figure 1: Experimental protocol of liver fibrosis induction and of ADHLSC injection in 
SCID Beige mice. 
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Preliminary results showed an improved survival rate in the group of 
mice treated with CCL4 and transplanted with ADHLSCs, as compared 
to CCL4 treated and sham operated ones. The mortality in the groups 
previously treated with CCl4 can be explained by the fact that the dose 
of Temgesic (136 µg/kg) given during the postoperative care was too 
high for mice presenting an hepatocellular insufficiency. This 
hypothesis was confirmed by a second experiment in which a lower 
dose of Temgesic (22.5 µg/kg) was used. 
Analysis of recovered livers revealed a reduction of liver fibrosis with 
thinner collagen septa after injection of ADHLSCs, as demonstrated by 
Sirius Red staining (Figure 2).  
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Figure 2: Sirius red staining in livers of SCID-Beige mice treated with CCl4 and 
intrasplenically injected either with the vehicle (PBS/NAC) or with ADHLSC. 
Magnification 40x. 
  
In serial slices, we demonstrated that ASMA immunostaining was lower  
in the group transplanted with ADHLSCs, attesting to the presence of 
less activated HSCs (Figure 3), which is in correlation with the previous 
results. The decrease of ASMA was confirmed at the gene expression 
level, as illustrated in figure 4. 
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Figure 3: ASMA immunostaining in livers of SCID-Beige mice treated with CCl4 and 
intrasplenically injected either with the vehicle (PBS/NAC) or with ADHLSC. 
Magnification 100x. 
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Figure 4: Gene expression of ASMA and Collagen Ia1 in the liver of SCID Beige mice  
treated with CCl4 and intrasplenically injected either with the vehicle (Ctrl) or with  
ADHLSC. 
 
The analysis of the mice liver function revealed a tendency of a  
decrease in the level of ALT in the transplanted mice as compared to the  
control group (figure 5), which  suggests an improvement of liver 
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function after cell transplantation. Two mice in the transplanted group 
have even reached the normal range. 
 
 
 
Figure 5: ALT levels in the serum of SCID Beige mice treated with CCl4 and 
intrasplenically injected either with the vehicle (Control mice) or with 
ADHLSC (transplanted mice). 
 
Even preliminary, these results remain promising. Further studies will 
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include a larger number of animals as well as cells of different donors to 
get a clear cut information on the potential of ADHLSC to modulate the  
degree of liver fibrosis. The underlying mechanisms will also be studied  
and the effect of the secretome will be evaluated in vivo.  
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General discussion 
 
Liver fibrosis represents the consequence of a sustained wound healing 
process in response to chronic injury. The causes are numerous, 
including viral, autoimmune, drug induced, cholestatic and metabolic. 
Cirrhosis represents the end stage evolution of liver fibrosis, resulting 
in nodular transformation and loss of normal parenchymal architecture, 
impaired vascular flow and progressive impairment of the hepatic 
function. With hundreds of millions patients affected worldwide, 
cirrhosis represents a major public health issue [1]. 
The most effective treatment available nowadays remains orthotopic 
liver transplantation (OLT). However, organ shortage, operative risks, 
post-transplant complications and recurrence of the pre-existing liver 
disease underline the necessity to develop alternative therapeutic 
strategies [2]. Moreover, fibrosis can develop into the liver grafts. 
Transplant-related factors such as cold ischemia time and biliary 
complications are known to play a role in this phenomenon [3] [4].  
Acting earlier on the progressive fibrous tissue deposition may prevent 
this ultimate stage. 
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It is now widely acknowledged that liver fibrosis is a dynamic and 
potentially reversible process  [5]. A better understanding of liver 
fibrosis physiopathology is useful to define the strategic points of an 
optimal therapeutic intervention. Several strategies are currently 
focusing on reducing inflammation, protecting host hepatocytes, 
inhibiting HSC activation, stimulating activated HSC apoptosis, or 
directly modulating the extracellular matrix and improving its 
degradation.  
 
Several drugs have been developed in order to meet these targets and 
their use has been reported in several preclinical and clinical studies. 
Although some preclinical studies have shown promising results, the 
efficacy of such therapies has not been proven in humans [6] [1] [7]. 
Differences in pharmacokinetics and in collagen cross linking between 
rodents and humans can probably explain these contradictory results. 
Moreover, most clinical studies are performed during a limited period 
of time while fibrosis takes years to develop. A longer follow-up period 
is probably needed in order to establish the efficacy of the drugs. 
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Over the past few years, cell-based therapy has progressively emerged 
as a potential promising alternative to OLT for patients suffering from 
metabolic disorders [8]. This less invasive technique has been proposed 
to treat liver fibrosis because of the ability of stem cells to improve the 
hepatic inflammatory microenvironment, inhibit the activation or 
induce apoptosis of HSC, replace damaged hepatocytes and promote the 
regeneration of residual hepatocytes [9]. Cell-based therapy presents 
the advantage to meet several targets and to have a durable action 
following engraftment in the liver parenchyma. Mesenchymal stem cells 
(MSCs) seem to be a promising candidate, because of their safer profile 
as compared to embryonic stem cells and induced pluripotent stem 
cells [10]. In vivo studies using MSCs to treat induced liver fibrosis have 
shown promising results [11] [12] [13]. A decrease of liver fibrosis is 
accompanied by a frequent improvement of the liver functions. 
However, there is no consensus regarding the exact mechanisms by 
which MSCs exert their beneficial effect and the interactions between 
MSCs and activated HSCs are not evaluated in such models.  In human, 
the injection of MSCs has been followed by the improvement of the liver 
function in several clinical studies [14] [15], even among patients 
presenting an advanced stage of liver fibrosis. The MSCs used in the 
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different studies are of extra-hepatic origin (bone marrow, adipose 
tissue, umbilical cord). The beneficial effects were observed regardless 
of the origin of MSCs, even if the superiority in terms of 
immunomodulation has been demonstrated in vitro for adipose tissue-
derived MSCs in comparison with bone marrow-derived MSCs [16]. 
In the current work, we investigated the anti-fibrotic properties of 
mesenchymal stem/ progenitor cells derived from the adult healthy 
human liver (ADHLSCs). These cells display characteristics described to 
be potentially associated to anti-fibrotic effects, such as the 
immunoregulatory properties and the differentiation potential, as 
described for extra-hepatic MSCs [17] [18]. However, in contrary with 
extra-hepatic MSCs, ADHLSCs have a predetermination to differentiate 
into hepatocyte-like cells both in vitro and in vivo and have the 
potential to participate to liver regeneration [18] [19] [20]. 
As HSCs represent the main cell type implicated in the extracellular 
matrix production, we investigated the ability of ADHLSCs to modulate 
HSC activation. 
Even if HSCs are derived from the liver non-parenchymal fraction and 
ADHLSCs from the parenchymal fraction, we noticed a similarity in cell 
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morphology and proliferation potential. Moreover, numerous markers 
were expressed in both cell types, making it difficult to differentiate the 
two cell populations using the classical techniques used to characterize 
MSCs. Therefore, we extensively compared both cell populations, in 
order to propose tools allowing their discrimination. The comparative 
studies were performed on both cell populations isolated from the same 
donor.  
The data of the current study revealed that HSC and ADHLSC are two 
different cell populations characterized by distinct gene expression and 
secretion profiles [21].  
 
Thanks to this part of the work, we demonstrated a high expression 
level of HGF by ADHLSCs, a growth factor known to display anti-fibrotic 
properties [22] [23], like inhibiting TGFb pathway and inducing 
metalloproteinases expression and activity [24], as well as up-
regulating miR-29 expression and thereby regulating collagen 
expression/secretion [25]. 
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ADHLSCs also expressed higher levels of some metalloproteinases, such 
as MMP3, MMP2 and MM14, known to have anti-fibrotic properties as 
they are able to degrade several components of the extracellular matrix 
[26]. 
In parallel, we performed a functional analysis of ADHLSCs and HSCs by 
analyzing their secretion profile in basal conditions. These experiments 
allowed us to 1) confirm the singularity of each cell type and 2) support 
the hypothesis that ADHLSCs could potentially have anti-fibrotic 
properties, as they secrete cytokines of therapeutic and immuno-
modulatory importance. 
Indeed, we demonstrated that ADHLSCs highly secreted HGF, as well as 
anti-inflammatory cytokines (IL1-ra, IL-4, IL-10 and IL-13) and 
interferon gamma, an inhibitor of collagen deposition and HSC 
activation [27]. 
These results may suggest an anti-fibrotic potential of ADHLSCs, as it 
has been shown for other types of MSCs [28] [11].  
In order to confirm the hypothesis that ADHLSC could have anti-fibrotic 
properties, we evaluated their ability to modulate the features 
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displayed by HSC after in vitro activation process. Indirect co-culture 
systems were used to answer this question. The model was developed 
because paracrine mechanisms have mainly been described to be 
implicated in the interactions between extra-hepatic MSCs and HSCs 
[29] [30] [31]. Moreover, the activation process of HSCs can be 
mimicked in vitro, as HSCs are in contact with the plastic dishes [32].  
We demonstrated that autologous and allogeneic ADHLSCs were able to 
inhibit HSC proliferation, a major feature of HSC activation process. 
Soluble factors constitutively secreted by ADHLSCs seem to be 
implicated as the observed effects could also be obtained using ADHLSC 
conditioned medium.  
The potent effect was observed with different ADHLSC/ HSC ratios 
(1/100, 1/10 and 1/1), but the effect was more pronounced with a ratio 
of 1 ADHLSC for 100 HSCs. We can make the assumption that an 
inhibitory molecule may be highly secreted by HSCs at high ADHLSC/ 
HSC ratios or that the implicated soluble factor(s) exert its action more 
efficiently at a determined concentration. In other published in vitro 
studies, extra-hepatic MSCs inhibit HSC proliferation in a dose-
dependent manner [30] [29]. These differences may result from the fact 
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that extra-hepatic human MSCs and animal HSCs were used in these 
published studies while MSCs derived from the human liver and human 
HSCs were used in the current work. Species differences have been 
reported for HSCs [33]. Desmin is expressed in quiescent rat HSCs but 
not in quiescent human HSCs. ASMA is expressed in quiescent human 
HSCs but only in activated rat HSCs. Differences in receptor expression 
also underline the interest to use human HSCs in preclinical studies 
[34]. The fact that only a small number of ADHLSCs is needed to exert 
the therapeutic effect and the fact that allogeneic cells can be used seem 
attractive in a context of cell-based therapy.  
 
Beside HSC proliferation inhibition, we also demonstrated that 
ADHLSCs were able to inhibit HSC pro-collagen type I secretion, after 
24 hours of co-culture. As collagen type I represents the major 
component of the extracellular matrix, inhibition of collagen type I 
secretion represents an interesting therapeutic option to control liver 
fibrosis development.  
In addition to previous studies, we also demonstrated that ADHLSCs 
were able to induce the production of anti-fibrotic molecules (such as 
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HGF, IL-6, MMP1 and MMP2) by HSCs themselves, suggesting the co-
implication of an autocrine loop of HSCs in the effects observed after co-
culture. 
Even if MMP2 has been shown to be implicated in extracellular matrix 
turnover during tissue repair process (including degradation of 
collagen IV, laminin and fibronectin), its expression is increased during 
fibrogenesis [35] [36]. HSCs produce this enzyme during liver injury and 
both human and rat HSCs increase their expression of MMP2 during 
their activation process in vitro [36]. In the current study, we observed 
an increase in the secretion level of MMP2 by HSCs together with an 
inhibition of HSC activation process. These results may be explained by 
an alteration in the MMP/TIMP expression ratio, known to be critical in 
determining matrix remodelling, as it has been demonstrated for N-Myc 
downstream-regulated gene 2 (NDRG2) [37] [38]. In this study, NDRG2 
induced an increase in the ratio MMP2 to TIMP2 and was able to inhibit 
HSC activation and to ameliorate liver fibrosis [37]. Further studies 
evaluating the secretion level of TIMPs by HSCs after co-culture with 
ADHLSCs and the activity of MMPs would be of great interest to 
understand the underlying mechanisms. 
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In order to investigate the mechanisms by which ADHLSCs could exert 
their effect on HSCs, we blocked the secretion of HGF, a growth factor 
highly secreted by ADHLSCs, as previously discussed. 
HGF neutralization resulted in a partial reversion of HSC proliferation 
and pro-collagen secretion inhibition, suggesting that this growth factor 
is implicated (at least in part) in the observed effect on HSCs. 
These results are in accordance with the previous data describing the 
ability of HGF to inhibit the PDGF-mediated over-proliferation of 
myofibroblasts in rat kidneys and to inhibit the pro-fibrogenic TGF-β 
pathway [24]. 
We demonstrated that the induction of anti-fibrotic molecules secretion 
by HSCs is also partially mediated by HGF. HGF is known to be able to 
induce MMP secretion by lung myofibroblasts [24]. If MMP1 and 2 are 
implicated in extracellular matrix degradation, IL-6 is involved in 
regeneration and survival of hepatocytes and can act synergistically 
with MSCs to reduce fibrosis in mice [39] [40].  
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A larger screening of ADHLSC secretome would be useful to identify the 
other factor(s) possibly implicated in the observed effects.  
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Perspectives 
 
There is a growing evidence that MSCs can exert their therapeutic 
effects via the secretion of bioactive factors [41]. This is supported by i) 
the demonstrated ability of MSCs to exert therapeutic effects without a 
significant incidence or duration of engraftment in the transplanted 
animals and ii) the potential of MSC-conditioned medium to exert 
therapeutic effects, such as promoting liver regeneration in an animal 
model of acute liver injury [41] [42]. The paracrine activity of MSCs 
together with the modulation of inflammation, probably create a 
microenvironment favorable for tissue regeneration. 
Beside cytokines and growth factors, MSC secretome also contains 
extracellular vesicles, including exosomes and microvesicles. Exosomes 
(50-100 nm in diameter) are vesicles generated by exocytosis of 
multivesicular bodies, while microvesicles (100-1000 nm in diameter) 
are generated by budding of the plasma membrane [41].  These 
extracellular vesicles contain proteins, as well as microRNA and RNA. In 
the context of liver fibrosis, transplantation of exosomes derived from 
human umbilical cord MSC was shown to alleviate CCl4-induced liver 
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fibrosis by inhibiting epithelial to mesenchymal transition (EMT) and 
by protecting hepatocytes [43]. 
The implication of extracellular vesicles in the paracrine modulation of 
HSC by ADHLSC is worth to be explored in the future, in parallel with a 
large screening of cytokines and growth factors contained in ADHLSC 
conditioned medium. 
The in vitro model allows the study of the mechanisms involved in the 
interactions between ADHLSCs and HSCs. However, it presents some 
limitations as the whole organ is not intact. The influence of the 
different systems present in a living organism (nervous, immune, 
endocrine, circulatory,…) is not evaluated in vitro. 
Such questions can be addressed in vivo. We have shown promising 
preliminary results of an in vivo study which evaluated the influence of 
ADHLSCs in an animal model of induced liver fibrosis. We observed a 
decrease of liver fibrosis in the group of mice transplanted with 
ADHLSCs. A second study is currently ongoing to confirm the data with 
a higher number of animals. 
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Moreover, the study of the mechanisms involved would be of great 
interest and might deserve a new PhD thesis work. Several hypotheses 
can be made, including 1) the differentiation of ADHLSC into 
hepatocyte-like cells, 2) the promotion of liver regeneration, 3) the 
secretion of MMP, 4) the improvement of the inflammatory 
microenvironment, 5) the modulation of HSC activation.  
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General conclusion 
 
This work takes place in the context of MSC-based therapy development 
for the treatment of liver fibrosis. A first comparative study allowed us 
to point out several characteristics of ADHLSCs (including their 
secretion profile), that could suggest their potential anti-fibrotic 
properties. In vitro studies confirmed this hypothesis and revealed the 
ability of ADHLSCs to modulate the features displayed by HSCs after 
their in vitro activation. Beside the inhibition of HSC proliferation and 
collagen secretion, ADHLSCs were also able to induce the secretion of 
anti-fibrotic molecules by HSCs themselves, suggesting a possible co- 
implication of an autocrine loop of HSCs in the anti-fibrotic process 
induced by ADHLSCs. Our study highlights the role of HGF as a part of 
the potential mechanism involved. These results provide new insights 
in the mechanisms underlying the anti-fibrotic effects of MSCs, as HSCs 
themselves could be implicated in the therapeutic process. Additional in 
vitro and in vivo studies should support the potential development of 
ADHLSC cell-based systems in the treatment of liver fibrosis. 
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